<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88849</article-id><article-id pub-id-type="doi">10.7554/eLife.88849</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88849.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>SIV-specific neutralizing antibody induction following selection of a PI3K drive-attenuated <italic>nef</italic> variant</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0708-9373</contrib-id><email>h-yamato@niid.go.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund17"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Matano</surname><given-names>Tetsuro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3096-6749</contrib-id><email>tmatano@niid.go.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/001ggbx22</institution-id><institution>AIDS Research Center, National Institute of Infectious Diseases</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04k51q396</institution-id><institution>Department of Biomedicine, University Hospital Basel</institution></institution-wrap><addr-line><named-content content-type="city">Basel</named-content></addr-line><country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02cgss904</institution-id><institution>Joint Research Center for Human Retrovirus Infection, Kumamoto University</institution></institution-wrap><addr-line><named-content content-type="city">Kumamoto</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>The Institute of Medical Science, The University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role>Reviewing Editor</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>03</month><year>2025</year></pub-date><volume>12</volume><elocation-id>RP88849</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-06-03"><day>03</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-04-24"><day>24</day><month>04</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.19.537602"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-08-08"><day>08</day><month>08</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88849.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-25"><day>25</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88849.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-13"><day>13</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88849.3"/></event></pub-history><permissions><copyright-statement>© 2023, Yamamoto and Matano</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Yamamoto and Matano</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88849-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88849-figures-v1.pdf"/><abstract><p>HIV and simian immunodeficiency virus (SIV) infections are known for impaired neutralizing antibody (NAb) responses. While sequential virus–host B cell interaction appears to be basally required for NAb induction, driver molecular signatures predisposing to NAb induction still remain largely unknown. Here we describe SIV-specific NAb induction following a virus–host interplay decreasing aberrant viral drive of phosphoinositide 3-kinase (PI3K). Screening of seventy difficult-to-neutralize SIV<sub>mac239</sub>-infected macaques found nine NAb-inducing animals, with seven selecting for a specific CD8<sup>+</sup> T-cell escape mutation in viral <italic>nef</italic> before NAb induction. This Nef-G63E mutation reduced excess Nef interaction-mediated drive of B-cell maturation-limiting PI3K/mammalian target of rapamycin complex 2 (mTORC2). In vivo imaging cytometry depicted preferential Nef perturbation of cognate Envelope-specific B cells, suggestive of polarized contact-dependent Nef transfer and corroborating cognate B-cell maturation post-mutant selection up to NAb induction. Results collectively exemplify a NAb induction pattern extrinsically reciprocal to human PI3K gain-of-function antibody-dysregulating disease and indicate that harnessing the PI3K/mTORC2 axis may facilitate NAb induction against difficult-to-neutralize viruses including HIV/SIV.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HIV</kwd><kwd>SIV</kwd><kwd>neutralizing antibody</kwd><kwd>Nef</kwd><kwd>PI3K</kwd><kwd>immunosignaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Rhesus macaque</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP24fk0410066</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP21jk0210002</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>24K21287</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>21H02745</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007449</institution-id><institution>Takeda Science Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Imai Memorial Trust for AIDS Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008734</institution-id><institution>Mitsui Sumitomo Insurance Welfare Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP22wm0325006</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP19fm0208017</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20fk0410022</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP18fk0410003</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20fk0410011</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20fk0108125</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20jm0110012</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP21fk0410035</award-id><principal-award-recipient><name><surname>Matano</surname><given-names>Tetsuro</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>17H02185</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>18K07157</award-id><principal-award-recipient><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Attenuation of viral Nef-driven PI3 kinase signaling in B cells precedes the induction of neutralizing antibody responses against a difficult-to-neutralize simian immunodeficiency virus.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Virus-specific neutralizing antibody (NAb) responses by B cells are induced by an intricate cooperation of adaptive immune cells (<xref ref-type="bibr" rid="bib52">Kumar et al., 2010</xref>; <xref ref-type="bibr" rid="bib102">Shulman et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Gitlin et al., 2014</xref>; <xref ref-type="bibr" rid="bib113">Wang et al., 2014</xref>) and often play a central role in clearance of acute viral infections (<xref ref-type="bibr" rid="bib45">Junt et al., 2007</xref>). In contrast, persistence-prone viruses such as human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and lymphocytic choriomeningitis virus (LCMV) variously equip themselves with B cell/antibody-inhibitory countermeasures (<xref ref-type="bibr" rid="bib70">Moir et al., 2001</xref>; <xref ref-type="bibr" rid="bib67">Mattapallil et al., 2005</xref>; <xref ref-type="bibr" rid="bib104">Sommerstein et al., 2015</xref>; <xref ref-type="bibr" rid="bib94">Sammicheli et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Fallet et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Mason et al., 2016</xref>), impairing NAb induction (<xref ref-type="bibr" rid="bib57">Levesque et al., 2009</xref>; <xref ref-type="bibr" rid="bib69">Mikell et al., 2011</xref>). These viruses successfully suppress elicitation of potent NAb responses, especially in acute infection (<xref ref-type="bibr" rid="bib35">Hunziker et al., 2003</xref>; <xref ref-type="bibr" rid="bib111">Tomaras et al., 2008</xref>), and establish viral persistence, posing considerable challenges for developing protective strategies. In particular, HIV and SIV establish early a large body of infection in vivo from early on with a distinct host genome-integrating retroviral life cycle (<xref ref-type="bibr" rid="bib114">Whitney et al., 2014</xref>). In addition, these lentiviruses are unique in launching a matrix of host immune-perturbing interactions mainly by their six remarkably pleiotropic accessory viral proteins, which optimally fuels viral pathogenesis (<xref ref-type="bibr" rid="bib51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="bib100">Sheehy et al., 2002</xref>; <xref ref-type="bibr" rid="bib29">Harris et al., 2003</xref>; <xref ref-type="bibr" rid="bib98">Schindler et al., 2006</xref>; <xref ref-type="bibr" rid="bib77">Neil et al., 2008</xref>; <xref ref-type="bibr" rid="bib121">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Laguette et al., 2011</xref>; <xref ref-type="bibr" rid="bib118">Yamada et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Joas et al., 2018</xref>; <xref ref-type="bibr" rid="bib55">Langer et al., 2019</xref>; <xref ref-type="bibr" rid="bib120">Yan et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Joas et al., 2020</xref>; <xref ref-type="bibr" rid="bib49">Khan et al., 2020</xref>; <xref ref-type="bibr" rid="bib112">Volcic et al., 2020</xref>; <xref ref-type="bibr" rid="bib91">Reuschl et al., 2022</xref>). A body of evidence has depicted this in the last decades, whereas its entity, including focal mechanisms of humoral immune perturbation in HIV/SIV infection, remains elusive to date.</p><p>Adverse virus–host interactions in HIV/SIV infection lead to a detrimental consequence of the absence of acute-phase endogenous NAb responses. Contrasting this, we and others have previously described in in vivo experimental models that passive NAb infusion in the acute phase can trigger an endogenous T-cell synergism, resulting in robust control of SIV and chimeric SHIV (simian/human immunodeficiency virus) (<xref ref-type="bibr" rid="bib27">Haigwood et al., 1996</xref>; <xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib78">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="bib80">Nishimura et al., 2017</xref>). This indicates that virus-specific NAbs not only confer sterile protection but also can evoke T-cell-mediated non-sterile viral control, suggesting the importance of endogenous NAb responses supported by humoral-cellular response synergisms, during an optimal time frame. Therefore, identifying the mechanisms driving NAb induction against such viruses is an important step to eventually design NAb-based HIV control strategies.</p><p>One approach that can provide important insights into this goal is the analysis of in vivo immunological events linked with NAb induction against difficult-to-neutralize SIVs in a non-human primate model. Various in vivo signatures of HIV-specific NAb induction, such as antibody-NAb coevolution (<xref ref-type="bibr" rid="bib72">Moore et al., 2012</xref>), autoimmune-driven induction (<xref ref-type="bibr" rid="bib71">Moody et al., 2016</xref>), and natural killer cell-related host polymorphisms (<xref ref-type="bibr" rid="bib10">Bradley et al., 2018</xref>), have been reported to date. The broad range of contributing factors collectively, and interestingly, indicates that pathways to NAb induction against difficult-to-neutralize viruses including HIV/SIV are redundant, and may potentially involve as-yet-unknown mechanisms driving NAb induction. For example, the neutralization resistance of certain SIV strains does not appear to be explained by any of the aforementioned, posing SIV models as attractive tools to analyze NAb induction mechanisms.</p><p>In the present study, we examined virus-specific antibody responses in rhesus macaques infected with a highly difficult-to-neutralize SIV strain, SIV<sub>mac239</sub>. This virus is pathogenic in rhesus macaques causing simian AIDS across a broad range of geographical origin of macaques (<xref ref-type="bibr" rid="bib15">Cumont et al., 2008</xref>). Macaques infected with SIV<sub>mac239</sub> show persistent viremia and generally lack NAb responses throughout infection (<xref ref-type="bibr" rid="bib48">Kestler et al., 1991</xref>; <xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>). In this study, a large-scale screening of SIV<sub>mac239</sub>-infected Burmese rhesus macaques for up to 100 weeks identified a subgroup inducing NAbs in the chronic phase. Interestingly, before NAb induction, these animals commonly selected for a specific CD8<sup>+</sup> cytotoxic T lymphocyte (CTL) escape mutation in the viral Nef-coding gene. Compared with wild-type (WT) Nef, this mutant Nef manifested a decrease in aberrant interaction with phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin complex 2 (mTORC2), resulting in decreased downstream hyperactivation of the canonical B-cell negative regulator Akt (<xref ref-type="bibr" rid="bib83">Omori et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">Limon et al., 2014</xref>). Machine learning-assisted imaging cytometry revealed that Nef preferentially targets Env-specific B cells in vivo. Furthermore, the NAb induction was linked with sustained Env-specific B-cell responses after or during the mutant Nef selection. Thus, NAb induction in SIV<sub>mac239</sub>-infected hosts conceivably involves a functional boosting of B cells that is phenotypically reciprocal to a recently found human PI3K gain-of-function and antibody-dysregulating inborn error of immunity (IEI), activated PI3 kinase delta syndrome (APDS) (<xref ref-type="bibr" rid="bib4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Lucas et al., 2014</xref>). Our results suggest that intervening PI3K/mTORC2 signaling can potentially result in harnessing NAb induction against difficult-to-neutralize viruses.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Identification of macaques inducing SIV<sub>mac239</sub>-neutralizing antibodies</title><p>We performed a retrospective antibody profile screening in rhesus macaques infected with NAb-resistant SIV<sub>mac239</sub> (n = 70) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and identified a group of animals inducing anti-SIV<sub>mac239</sub> NAb responses (n = 9), which were subjected to characterization. These NAb inducers showed persistent viremia with no significant difference in viral loads compared with a subgroup of NAb non-inducers (n = 19) that were previously profile-clarified, naïve, and major histocompatibility complex class I (MHC-I) haplotype-balanced (used for comparison hereafter) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Plasma SIV<sub>mac239</sub>-NAb titers measured by 10 TCID<sub>50</sub> SIV<sub>mac239</sub> virus-killing assay showed an average maximum titer of 1:16, being induced at an average of 48 weeks post-infection (p.i.) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Two of the nine NAb inducers showed detectable NAb responses by 24 weeks p.i., while the remaining seven induced NAbs after 30 weeks p.i. Anti-SIV<sub>mac239</sub> neutralizing activity was confirmed in immunoglobulin G (IgG) purified from plasma of these NAb inducers (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). SIV Env-binding IgGs developed from early infection in both NAb inducers and non-rapid-progressing NAb non-inducers, the latter differing from rapid progressors known to manifest serological failure (<xref ref-type="bibr" rid="bib33">Hirsch et al., 2004</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>). Titers of Env-binding IgG were not higher but rather lower at year 1 p.i. in the NAb inducers (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B and C</xref>). This was consistent with other reports (<xref ref-type="bibr" rid="bib32">Havenar-Daughton et al., 2016</xref>) and differing with gross B-cell enhancement in Nef-deleted SIV infection with enhanced anti-SIV binding antibody titers accompanying marginal neutralization (<xref ref-type="bibr" rid="bib1">Adnan et al., 2016</xref>). NAb inducers and non-inducers showed similar patterns of variations in viral <italic>env</italic> sequences (<xref ref-type="bibr" rid="bib11">Burns et al., 1993</xref>), mainly in variable regions 1, 2 and 4 (V1, V2, and V4) (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Neutralizing antibody (NAb) induction against NAb-resistant SIV<sub>mac239</sub>.</title><p>(<bold>A</bold>) Study design. (<bold>B</bold>) Plasma viral loads (simian immunodeficiency virus [SIV] <italic>gag</italic> RNA copies/ml plasma) in NAb non-inducers (left) and inducers (right). (<bold>C</bold>) Plasma SIV<sub>mac239</sub> 100% neutralizing end point titers by 10 TCID<sub>50</sub> killing assay on MT4-R5 cells. Points on the dotted line show marginally NAb-positive results (&lt;1:2). In some animals, titers were comparable with our reported results using MT4 cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Profile of SIV<sub>mac239</sub>-NAb non-inducer subgroup cohort.</title><p>Summary of a SIV<sub>mac239</sub>-NAb non-inducer subgroup cohort (n = 19), composed from previously partially characterized, major histocompatibility complex class I (MHC-I) haplotype-balanced naïve animals. Symbols A+, B+, E+, J+, and D+ represent possession of MHC-I haplotypes <italic>90-120-Ia</italic>, <italic>90-120-Ib</italic>, <italic>90-010-Ie</italic>, <italic>90-088-Ij,</italic> and <italic>90-010-Id</italic>, respectively. For the titers, - represents negative; +/- represents neutralization in three out of four wells in a quadruplicate test. Gray shadings indicate euthanasia due to AIDS progression. Mamu-A and Mamu-B alleles of interest in this study are listed. These NAb non-inducers were previously partially reported for their plasma viral loads and MHC-I alleles (<xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Iwamoto et al., 2014</xref>). R01-011 was previously partially reported for NAb titers measured with the same method using MT4 cells as targets (<xref ref-type="bibr" rid="bib46">Kawada et al., 2007</xref>), which derived comparable results.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Source table for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88849-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>IgG class-switched neutralizing antibodies (NAbs) in the inducers.</title><p>Titration of SIV<sub>mac239</sub>-neutralizing IgGs in the NAb inducers. SIV<sub>mac239</sub>-specific IgGs, purified from pools of plasma with SIV<sub>mac239</sub>-specific NAb titers, were obtained from each animal as described (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>) and examined for their neutralizing activity by 10 TCID<sub>50</sub> SIV<sub>mac239</sub> killing on MT4-R5 cells. NAb-negative anti-SIV IgG and control IgG were prepared from a representative animal (R01-011) with NAb-negative plasma and pooled plasma of uninfected rhesus macaques, respectively.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Source table for <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88849-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Anti-SIV binding IgG profiles in neutralizing antibody (NAb) inducers and non-inducers.</title><p>(<bold>A</bold>) Temporal changes in SIV<sub>mac251</sub> Env gp120-specific antibody titers in the NAb non-inducers without rapid progression [NAb-negative non-rapid progressors, NAb(-) non-RPs] (left, n = 11) and NAb inducers [NAb(+)] (right, n = 9). NAb non-inducers showing rapid progression (euthanized with AIDS onset within approximately 1 year) were not included except for macaque R10-001 (shown in the left for aligned comparison). Samples for non-RPs R06-001 and R10-002 were unavailable. (<bold>B</bold>) Unpaired <italic>t</italic>-test of log-transformed anti-SIV Env Ab titers in NAb(-) non-RPs and NAb inducers. Bars represent geometric mean absorbance within each group. (<bold>C</bold>) Lysed SIV<sub>mac</sub> virion linear antigen-binding at year 1 post-infection (p.i.) in NAb(-) non-RPs (left, n = 12) and NAb inducers (right, n = 9). Plasma anti-SIV<sub>mac251</sub> IgGs were detected using a commercial western blotting system against the parental strain SIV<sub>mac251</sub> (ZeptoMetrix). White arrowheads indicate Env gp120-specific bands. Experiments were performed twice with comparable results. Bands were verified based on previous in-house purified, SIV-specific IgG results (<xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>).</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1—figure supplement 3—source data 1.</label><caption><title>PDF file containing original western blots for <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, labeling the corresponding viral protein bands and IDs.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88849-fig1-figsupp3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1s3sdata2"><label>Figure 1—figure supplement 3—source data 2.</label><caption><title>Original file for western blot analysis displayed in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88849-fig1-figsupp3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Env sequence variation pattern is not a major characteristic of neutralizing antibody (NAb) induction.</title><p>SIV<sub>mac239</sub> Env sequence variations before and after NAb induction. For each animal, the upper time point shows pre-induction and the lower time point (in purple) shows post-induction (first or second time point with NAb titer &gt;1:2). Dominant residue changes are shown as follows: gp120 (gray), variable regions V1-V5 (blue), and gp41 (blue gray). Subdominant mutations are uncolored. Unlabeled gray and black shadings show subdominant and dominant deletion of residues. Parental SIV<sub>mac239</sub> sequence is listed for V1-V5. Residues mutated in multiple animals within V1-V5 are shown in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig1-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Selection of a viral <italic>nef</italic> mutation (Nef-G63E) precedes chronic-phase SIV<sub>mac239</sub>-specific NAb induction</title><p>To explore viral mutations linked to NAb induction, we assessed viral nonsynonymous polymorphisms outside <italic>env</italic>. Strikingly, we found selection of a viral genome mutation resulting in G (glycine)-to-E (glutamic acid) substitution at residue 63 of Nef (Nef-G63E) in seven of the nine NAb inducers (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Two inducers that did not select Nef-G63E were the early inducers detected for NAb positivity before 24 weeks p.i. This 63rd residue lies in the unstructured N-terminus of Nef, flanked by two α-helices conserved in SIVmac/SIVsmm (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This region is generally polymorphic among HIV-1/HIV-2/SIV, occasionally being deleted in laboratory and primary isolate HIV-1 strains (<xref ref-type="bibr" rid="bib24">Geyer et al., 2001</xref>). AlphaFold2-based structure prediction did not derive palpable change except for low-probability disruption of the alpha helices (data not shown). This mutation was found only in 2 of the 19 NAb non-inducers, including one rapid progressor (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and selection was significantly enriched in the NAb inducers compared to the 19 non-inducers (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Analysis of Nef-G63E mutation frequencies in plasma viruses showed that Nef-G63E selection preceded or at least paralleled NAb induction (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Selection of a viral <italic>nef</italic> mutation (Nef-G63E) before neutralizing antibody (NAb) induction.</title><p>(<bold>A</bold>) Viral <italic>nef</italic> mutations in NAb inducers. A linear schema indicating Nef functional domains is aligned above. Mutations at time points with NAb<sup>-</sup> (indicated by white wedge; mostly before 6 months post-infection [p.i.]), NAb<sup>+/-</sup> (green wedge), and NAb<sup>+</sup> (purple wedge; mostly after 1 year) are shown in individual animals. Black and dark gray represent dominant and subdominant mutations (or deletion in R-360) by direct sequencing, respectively. Red and pink indicate dominant and subdominant G63E detection, respectively. (<bold>B</bold>) Schema of SIV<sub>mac239</sub> Nef structure and Nef-G63E mutation orientation. (<bold>C</bold>) Comparison of frequencies of macaques having Nef-G63E in plasma viruses between NAb non-inducers and inducers. Compared by Fisher’s exact test. (<bold>D</bold>) Temporal relationship of Nef-G63E frequencies in plasma virus and NAb induction. Black boxes (left Y axis) show log<sub>2</sub> NAb titers; red triangles and blue diamonds (right Y axis) show percentage of G63E and G63R mutations detected by subcloning (15 clones/point on average), respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>Nef-G63E is a CD8<sup>+</sup> T-cell escape mutation</title><p>To explore the mechanistic link between Nef-G63E selection and NAb induction, first we assessed whether CD8<sup>+</sup> T-cell responses target this region. We found that these seven NAb inducers selecting this mutation elicited CD8<sup>+</sup> T-cell responses specific for a 9-mer peptide Nef<sub>62–70</sub> QW9 (QGQYMNTPW) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This Nef<sub>62–70</sub> QW9 epitope is restricted by MHC-I molecules Mamu-B*004:01 and Mamu-B*039:01 (<xref ref-type="bibr" rid="bib18">Evans et al., 1999</xref>; <xref ref-type="bibr" rid="bib99">Sette et al., 2012</xref>). Possession of these accounted for six cases of Nef-G63E selection (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), and the remaining one animal possessed Mamu-A1*032:02 predicted to bind to Nef<sub>63–70</sub> GW8 (NetMHCpan). When compared, 10 of 19 NAb non-inducers also possessed at least one of these alleles (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This did not significantly differ with the NAb inducer group (p=0.25 by Fisher’s exact test, data not shown), indicating that NAb induction was not simply linked with possession of these MHC-I genotypes but instead required furthermore specific selection of the Nef-G63E mutation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Nef-G63E was confirmed to be an escape mutation from Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). NAb non-inducers possessing these alleles elicited little or no Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), suggesting that in vivo selection and fixation of this Nef-G63E SIV was indeed Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T cell-dependent. Replication of SIV carrying the Nef-G63E mutation was comparable with WT on a cynomolgus macaque HSC-F CD4<sup>+</sup> T-cell line (<xref ref-type="bibr" rid="bib2">Akari et al., 1996</xref>), excluding the possibility that the mutation critically impairs viral replication (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), and plasma viral loads were comparable between Nef-G63E mutant-selecting NAb inducers versus non-inducers (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). These results indicate NAb induction following in vivo selection and fixation of the CD8<sup>+</sup> T-cell escape <italic>nef</italic> mutation, Nef-G63E under viral persistence.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Nef-G63E is a CD8<sup>+</sup> T-cell escape mutation.</title><p>(<bold>A</bold>) Nef<sub>62–70</sub> QW9-specific CD8<sup>+</sup> T-cell frequencies and related major histocompatibility complex class I (MHC-I) alleles in seven neutralizing antibody (NAb) inducers selecting Nef-G63E. Mamu-B*039:01 and Mamu-B*004:01 are known to restrict Nef<sub>62–70</sub> QW9 epitope and binding of Nef<sub>63–70</sub> peptide to Mamu-A1*032:02 was predicted. (<bold>B</bold>) CD8<sup>+</sup> T-cell responses specific to wild-type (WT) Nef<sub>62–70</sub> or mutant Nef<sub>62–70</sub>.G63E or Nef<sub>62–70</sub>.G63R peptides.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Selection of Nef-G63E mutant simian immunodeficiency virus (SIV) is linked with Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell response positivity.</title><p>(<bold>A</bold>) Nef<sub>62-70</sub>-specific CD8+ T cell responses around week 20 post-SIV challenge in seven viremic NAb non-inducers possessing either of the major histocompatibility complex class I (MHC-I) alleles Mamu-B*039:01, Mamu-B*004:01 or Mamu-A1*032:02. (<bold>B</bold>) Temporal supernatant SIV p27 concentrations after wild-type (WT) or Nef-G63E mutant SIV infection at multiplicity of infection (MOI) 0.001 on HSC-F cells. Data represent one of two independent experiments performed in triplicate. Bars: mean ± SEM. (<bold>C</bold>) Comparison of plasma viral loads in Nef-G63E-selecting NAb non-inducers (n = 7) versus non-inducers at indicated time points post-SIV challenge. Bars represent geometric means. log10-transformed values are compared by unpaired <italic>t</italic>-tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>G63E mutation reduces aberrant Nef interaction-mediated drive of PI3K/mTORC2</title><p>We next focused on the functional phenotype of Nef-G63E mutant SIV in infected cells. An essence of host perturbation by Nef is its wide-spectrum molecular downregulation, ultimately facilitating viral replication (<xref ref-type="bibr" rid="bib97">Schindler et al., 2004</xref>; <xref ref-type="bibr" rid="bib121">Zhang et al., 2009</xref>). To evaluate possible amelioration of this property, we compared downregulation of major targets CD3, CD4, MHC-I, CXCR4, and BST-2 (<xref ref-type="bibr" rid="bib40">Jia et al., 2009</xref>) in infected HSC-F cells. Nef-G63E mutation did not confer notable change compared with WT (p=not significant [<italic>n.s</italic>.] for all molecules, data not shown), implicating other non-canonical changes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). One report suggested Nef to drive macrophage production of soluble ferritin and perturb B cells, with its plasma level correlating with viremia (<xref ref-type="bibr" rid="bib108">Swingler et al., 2008</xref>). Here, plasma ferritin levels showed no differences (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>) and viral loads were comparable as aforementioned between Nef-G63E-selecting NAb inducers and non-inducers, arguing against gross involvement of ferritin as well as other viral replication-related Nef phenotypes at least in this model.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Nef-G63E mutation reduces PI3K/mTORC2 binding and pAkt drive.</title><p>(<bold>A</bold>) Representative surface expression level histograms of CD3, CD4, major histocompatibility complex class I (MHC-I), CXCR4, and BST-2 in CD4<sup>lo</sup>Nef<sup>+</sup> subpopulations after wild-type (WT) or Nef-G63E mutant simian immunodeficiency virus (SIV) infection at multiplicity of infection (MOI) 0.1 on HSC-F cells. (<bold>B</bold>) Left: representative histograms of relative pAkt serine (Ser) 473 levels in p27<sup>+</sup> subpopulations after WT or Nef-G63E mutant SIV infection at MOI 0.1 on HSC-F cells. Numbers show pAkt Ser473 mean fluorescence intensities (MFIs) for each. Right: deviation of pAkt Ser473 MFIs in p27<sup>+</sup> HSC-F cells compared with mean MFI of uninfected cells. Compared by unpaired <italic>t</italic>-test. (<bold>C</bold>) Left: relative pAkt Ser473 levels (normalized to mean MFI of uninfected controls) in Nef<sup>+</sup> HSC-F cells assessed for serum starvation (MOI 0.2, 1 day post-infection [p.i.]). Adjusted p values show results of comparison via Sidak’s post hoc test of two-way ANOVA (C, left). Right: deviation of pAkt Ser473 MFIs in Nef<sup>+</sup> HSC-F cells assessed for high-MOI infection (MOI 5, 1 day p.i). Compared by unpaired <italic>t</italic>-test. (<bold>D</bold>) Proximity ligation assay (PLA) of Nef binding with mTOR, GβL/mLST8, PI3Kp85, and PI3Kp110α. MFI-based binding index was calculated as (anti-Nef/anti-partner) - (isotype/anti-partner) – (anti-Nef/isotype) + (isotype/isotype). Histograms for samples and isotype/isotype are representatively shown. Differences in MFI binding indexes can be enhanced compared with comparison of raw MFIs. Compared by paired <italic>t</italic>-tests. (<bold>E</bold>) Sin1 co-immunoprecipitation analysis of WT versus Nef-G63E mutant SIV-infected HSC-F cells (infected at MOI 0.05, day 3). Immunoblotting of Nef (37 kDa) in whole-cell lysates (lanes 4–6) and anti-Sin1 antibody immunoprecipitates (lanes 1–3) are shown. (<bold>F</bold>) Cell death frequencies of SIV-infected cells measured by Annexin V positivity (% of CD4<sup>lo</sup>) (infected at MOI 0.1, day 3). Compared by unpaired <italic>t</italic>-test. Data represent one of two (A–C, right) independent experiments in quadruplicate, four independent experiments performed in triplicate (C, left), four independent single-well comparison experiments pooled for statistical analysis (D), two experiments (E) or two experiments performed with six wells/control (F). Bars: mean ± SD (B, C right), mean ± SEM (C left, F).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4E</xref> indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88849-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Original file for the western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88849-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Decreased Akt hyperactivation properties of Nef-G63E mutant simian immunodeficiency virus (SIV).</title><p>(<bold>A</bold>) Plasma ferritin levels (ng/ml) in examined neutralizing antibody (NAb) non-inducers versus Nef-G63E mutant SIV-selecting NAb inducers around year 1 post-infection (p.i.). Bars represent mean in each group. Log-transformed values compared by unpaired <italic>t</italic>-test. (<bold>B</bold>) Relative levels of pAkt Ser473 (left panel) and threonine (Thr) 308 (right panel) in SIV Nef<sup>+</sup> HSR5.4 cells (multiplicity of infection [MOI] 0.1, 4 days p.i.). (<bold>C</bold>) Relative pAkt Ser473 levels in Nef<sup>+</sup> HSC-F cells without stimuli and transiently pulsed with IFN-γ, IL-2, or SIV<sub>mac</sub> Env gp130 after infection (MOI 0.2, 1 day). (<bold>D</bold>) Gene expression significantly differing between WT and Nef-G63E SIV infection (MOI 5, 1 day). Black bars show potentially Akt-related genes. Asterisks show dynamics concordant with the Nef-G63E phenotype (PI3K-pAkt Ser473 downstream downregulation or inhibition upregulation). (<bold>E</bold>) Representative flow cytometric gating (NAb inducer R01-012, week 30 p.i.) of peripheral blood CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory follicular CD4+ T cells. Cells were gated as CD3<sup>+</sup>CD8<sup>-</sup>CD4<sup>+</sup>CD95<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>CXCR3<sup>-</sup> live singlet PBMCs. Available samples of six NAb inducers showing peak Nef-G63E mutant selection around week 30 p.i. and 13 viremic NAb non-inducers were tracked. (<bold>F</bold>) Comparison of peripheral CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory Tfh cell frequencies between pre-SIV infection and around week 30 p.i. in examined NAb non-inducers developing disease before week 60 (left: n = 5) and alive more than 70 weeks (middle: n = 8) and Nef-G63E-detected NAb inducers alive more than 70 weeks (right: n = 6). Analyzed by Wilcoxon signed-rank tests. MFIs relative to those in uninfected controls (%) are shown. **p&lt;0.01, ***p&lt;0.001, n.s., not significant between WT and Nef-G63E mutant by unpaired <italic>t</italic>-tests (<bold>B, C</bold>). Data represent one of two (<bold>B, C</bold>) independent experiments performed in triplicate (C: unstimulated) or quadruplicate (B, C: PI3K-pulsed). Bars: mean ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Nef-G63R mutant simian immunodeficiency virus (SIV) properties.</title><p>(<bold>A</bold>) Comparison of frequencies of macaques selecting for Nef-G63R mutant in plasma between neutralizing antibody (NAb) non-inducers and inducers. Compared by Fisher’s exact test. (<bold>B</bold>) Temporal relationship of Nef G63R frequencies in plasma virus in a NAb non-inducer macaque R06-034 preferentially selecting for Nef-G63R but not Nef-G63E mutant. Black boxes (left Y axis) show log<sub>2</sub> NAb titers; red triangles and blue diamonds (right Y axis) show percentage of G63E and G63R mutations detected by subcloning (15 clones/point on average), respectively. (<bold>C</bold>) Left: representative histograms of relative pAkt serine (Ser) 473 levels in p27<sup>+</sup> subpopulations after WT, Nef-G63E, or Nef-G63R mutant SIV infection at multiplicity of infection (MOI) 0.1 on HSC-F cells. Numbers show pAkt Ser473 mean fluorescence intensities (MFIs) for each. Right: deviation of pAkt Ser473 MFIs in p27<sup>+</sup> HSC-F cells compared with mean MFI of uninfected cells. Analyzed by one-way ANOVA with Tukey’s post hoc multiple comparison tests. Data represent one of two independent experiments performed in quadruplicate with similar results.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Next, we elucidated immunosignaling-modulating properties of Nef-G63E SIV. Akt is known as the predominant immune-intrinsic negative brake of B-cell maturation and AFC/antibody responses in vivo (<xref ref-type="bibr" rid="bib83">Omori et al., 2006</xref>; <xref ref-type="bibr" rid="bib105">Srinivasan et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">Limon et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Fruman et al., 1999</xref>; <xref ref-type="bibr" rid="bib88">Ray et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Sander et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Luo et al., 2019</xref>). Thus, we analyzed Akt phosphorylation on day 3 after Nef-G63E SIV infection at low multiplicity of infection (MOI). This analysis revealed that its serine 473-phosphorylated form (pAkt Ser473), non-canonically known for Nef-mediated upregulation (<xref ref-type="bibr" rid="bib53">Kumar et al., 2016</xref>), was significantly lower in Nef-G63E mutant-infected cells compared with WT (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The difference observed here was more pronounced than histogram deviation levels in PI3K gain-of-function mice with full recapitulation of B-cell/antibody-dysregulating human APDS disease phenotype (<xref ref-type="bibr" rid="bib6">Avery et al., 2018</xref>). In contrast, the threonine 308-phosphorylated Akt (pAkt Thr308) level remained unaffected (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><p>Interestingly, external PI3K stimuli by serum starvation (<xref ref-type="bibr" rid="bib47">Kennedy et al., 1997</xref>) accelerated phenotype appearance from day 3 to day 1 p.i. (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, left). A similar trend was obtained by short-term PI3K stimulation with IFN-γ (<xref ref-type="bibr" rid="bib79">Nguyen et al., 2001</xref>), IL-2 (<xref ref-type="bibr" rid="bib64">Marzec et al., 2008</xref>), and SIV Env (<xref ref-type="bibr" rid="bib20">François and Klotman, 2003</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). A high-MOI SIV infection, comprising higher initial concentration of extracellular Env stimuli, also accelerated phenotype appearance from day 3 to day 1 p.i., with stronger pAkt reduction (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, right). These data indicate that the Akt-inhibitory G63E mutant Nef phenotype is PI3K stimuli-dependent. Transcriptome analysis signatured decrease in PI3K-pAkt-FoxO1-related genes in mutant SIV infection (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Given that Akt is also a survival mediator, Nef-G63E mutation may be T helper cell (Th)-cytopathic and decrease Th dysfunctional expansion (<xref ref-type="bibr" rid="bib9">Baumjohann et al., 2013</xref>), as had been observed in LCMV strain WE (<xref ref-type="bibr" rid="bib89">Recher et al., 2004</xref>) and chronic HIV/SIV (<xref ref-type="bibr" rid="bib26">Gray et al., 2011</xref>; <xref ref-type="bibr" rid="bib60">Lindqvist et al., 2012</xref>; <xref ref-type="bibr" rid="bib85">Petrovas et al., 2012</xref>) infections. Here, reduced chronic-phase peripheral CXCR3<sup>-</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup> memory follicular Th (Tfh), linked with antibody cross-reactivity in one cohort (<xref ref-type="bibr" rid="bib61">Locci et al., 2013</xref>), was somewhat in line with this notion (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E and F</xref>). We additionally examined another CTL escape mutant Nef-G63R, selected with marginal statistical significance primarily in early stage (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). This mutant did not associate with NAb induction in one control animal (R06-034) even upon preferential selection (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>) and Nef-G63R mutant was not similarly decreased in pAkt drive (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2C</xref>), implicating that the Nef-G63E mutation was more tightly linked with NAb induction in terms of an immunosignaling phenotype.</p><p>We further explored molecular traits of this decreased Akt hyperactivation. We reasoned that comparing endogenous Nef binding patterns would be adequate and analyzed SIV-infected HSC-F cells with a flow cytometry-based proximity ligation assay (PLA) (<xref ref-type="bibr" rid="bib56">Leuchowius et al., 2009</xref>; <xref ref-type="bibr" rid="bib7">Avin et al., 2017</xref>). We found that this Nef-G63E mutation causes significant decrease in Nef binding to PI3K p85/p110α and downstream mTORC2 components mTOR (<xref ref-type="bibr" rid="bib96">Sarbassov et al., 2005</xref>) and GβL/mLST8 (<xref ref-type="bibr" rid="bib50">Kim et al., 2003</xref>) in the CD4<sup>lo</sup>-SIV Gag p27<sup>+</sup> infected population (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Results were biochemically confirmed by a decrease in G63E-mutated Nef binding to the mTORC2-intrinsic cofactor Sin1 in coimmunoprecipitation analysis of infected HSC-F cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Collectively, the Nef-G63E mutation attenuates PI3K/mTORC2 signaling driven by aberrant Nef bridging, explaining decreased Akt Ser473 phosphorylation by mTORC2. These properties were in keeping with more pronounced apoptosis of CD4-downregulated/infected HSC-F cells upon Nef-G63E SIV infection (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Thus, Nef-G63E SIV is a mutant virus decreased in aberrant interaction/drive of B-cell-inhibitory PI3K/mTORC2 signaling, manifesting a molecular signature reciprocal to human APDS (<xref ref-type="bibr" rid="bib4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Lucas et al., 2014</xref>; <xref ref-type="bibr" rid="bib6">Avery et al., 2018</xref>).</p></sec><sec id="s2-5"><title>Targeting of lymph node Env-specific B cells by Nef in vivo</title><p>Next, we analyzed in vivo targeting of virus-specific B cells by Nef in lymph nodes to explore the potential B-cell-intrinsic influence of the Nef-G63E phenotype. Previously suggested influence of soluble Nef itself (<xref ref-type="bibr" rid="bib86">Qiao et al., 2006</xref>) and/or related host factors (<xref ref-type="bibr" rid="bib108">Swingler et al., 2008</xref>) may derive generalized negative influence on B cells. However, SIV antigen-specific binding antibody responses were rather decreased in NAb inducers (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), with comparable viral loads (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>) and ferritin levels (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), differing from the aforementioned literature stating positive correlation between the three. We surmised that some targeted Nef intrusion against Env-specific B cells may be occurring and that the decreased aberrant drive of Nef-PI3K/mTORC2 may result in their enhanced maturation in lymph nodes.</p><p>While reports (<xref ref-type="bibr" rid="bib116">Xu et al., 2009</xref>) histologically proposed Nef B-cell transfer, quantitative traits, for example, invasion frequency and influence on virus-specific B cells, have remained unvisited. One of the reasons is that intracellular Nef staining is dim (particularly for B cell-acquired Nef) and difficult to examine by conventional flow cytometry. To circumvent this issue, defining staining cutline using single-cell images potentially overcomes confounding technical hurdles, such as high Nef false-staining signals owing to pre-permeation rupture and post-permeation processing that derives biologically discontinuous staining and/or batch-inflated signals. Thus, we reasoned that at the expense of spatial information, sophisticating imaging cytometry would best visualize Nef-mediated B-cell perturbation in vivo. We analyzed lymph node B cells with Image Stream X MKII, with high-power (&gt;10-fold) antigen detection (e.g., molecules of equivalent soluble fluorochrome [MESF] 5 vs. MESF 80 in an average flow cytometer for FITC detection) ideal for detection/single-cell verification.</p><p>We designed a triple noise cancellation strategy to overcome the issues stated above. Firstly, amine reactive dye staining (<xref ref-type="bibr" rid="bib84">Perfetto et al., 2006</xref>) gated out B cells being Nef-positive due to pre-experimental membrane damage (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, left). Next, we deployed secondary quantitative parameters of Nef signals deriving from each pixel of the images. Generation of a gray-level cooccurrence matrix (GLCM) (<xref ref-type="bibr" rid="bib28">Haralick et al., 1973</xref>), which computes adjacent signal deviation as their frequencies on a transpose matrix, enables calculation of a variety of feature values summarizing traits of the whole image. A biological assumption of Nef signal continuity in a true staining suggested that the sum of weighted square variance of GLCM, that is, the {sum of [square of (value – average signal strength)×frequency of each value occurrence]} would separate natural versus artificial Nef signals. This value, known as Haralick variance, was computed for multiple directions and averaged. The resultant Haralick variance mean (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, X-axis) is proportionate with unnaturalness of signals in the Nef channel. Finally, Nef signal intensity threshold (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>, Y-axis) gated out overtly stained cells void for true-false verification. These measures excluded B cells with non-specific, strong-signal binary-clustered staining pixels for Nef (deriving a large summated variance: X-axis and/or batch-stained for Nef: Y-axis; likely originating from post-experimental membrane damage).</p><p>Using this approach, we successfully acquired images of viable Nef<sup>+</sup>CD19<sup>+</sup> B cells with low Nef signal Haralick variance mean and low Nef signal intensity threshold, with fine-textured gradation of low-to-intermediate Nef staining with continuity from membrane-proximal regions and without sporadic staining speckles (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Scoring segregation of typical void/valid images by a linear discriminant analysis-based machine learning module showed that this gating provides the highest two-dimensional separation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Combined with visualization of Env-binding B cells, we reproducibly obtained images of Env-specific (Ch 12) CD19<sup>+</sup> (Ch 11) B cells without membrane ruptures (Ch 08) and showing fine-textured transferred Nef (Ch 02) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Nef invasion upregulated pAkt Ser473 (Ch 03) to a range resembling in vitro analysis (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), demonstrating that Nef-driven aberrant PI3K/mTORC2 signaling does occur in Nef-invaded B cells in vivo. Strikingly, lymph node Env-specific B cells showed significantly higher Nef-positive frequencies as compared with batch non-Env-specific B cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This indicated that infected cell-derived Nef preferentially targets adjacent Env-specific B cells, putatively through its contact/transfer from infected CD4<sup>+</sup> cells to B cells (<xref ref-type="bibr" rid="bib116">Xu et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Hashimoto et al., 2016</xref>). Thus, the phenotypic change in Nef can directly dictate Env-specific B-cell maturation.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Preferential targeting of lymph node Env-specific B cells by Nef in vivo.</title><p>(<bold>A</bold>) Representative gating of triple noise cancellation in vivo Nef staining in B cells analyzed using ImageStreamX MKII. Pre-experimental damaged cells are first excluded with Live/Dead from focused/centroid/singlet image-acquired CD19<sup>+</sup> B cells (first lane right/R4 gated on ‘Focused’). Following Nef<sup>+</sup> gating (second lane left/R5 gated on R4), a second step of Nef noise cancellation (second lane middle/R7 on R5) comprises double-negative removal of post-experimental stochastic irregular staining building a disparate intracellular staining gradient (X-axis, Nef signal pixel Haralick variance mean) and post-experimental batch overt cellular staining (Y-axis, Nef signal pixel intensity threshold). This outputs a B-cell population with a fine-textured pericellular Nef<sup>int-lo</sup> staining, biologically concordant with Nef membrane-anchoring. Probing of anti-Env BCR (αEnv) by recombinant SIV Env (second lane, right) is combined, resulting in a 2-D panel of intracellular Nef versus αEnv for noise-cancelled Nef<sup>+</sup> B cells (R7) plus Nef<sup>-</sup> B cells (R8) (third lane left/’R7+R8’). pAkt Ser473 expression (third lane right) and cellular morphology (<bold>B</bold>) was further analyzed. DN, double-negative. (<bold>B</bold>) Typical images of Nef-transferred Env-specific B cells defined αEnv<sup>+</sup>-intracellular Nef<sup>+</sup>-Nef Haralick variance mean<sup>lo</sup>-Nef Intensity threshold<sup>lo</sup>-Live/Dead<sup>-</sup>-CD19<sup>+</sup> cells (‘Nef<sup>+</sup>aEnv<sup>+’</sup> population of the lower-left panel in <bold>A</bold>, gated on ‘R7, R8’). Note the pericellular pAkt Ser473 upregulation in these cells (Ch 03/yellow). Data on inguinal lymph node lymphocytes of macaque R10-007 at week 62 post-SIV<sub>mac239</sub> infection are shown in (<bold>A</bold>) and (<bold>B</bold>). (<bold>C</bold>) Comparison of pAkt Ser473 median fluorescence (medFI) intensity levels in Nef<sup>-</sup> B cells (R8) versus noise-cancelled Nef<sup>+</sup> B cells (R7). Analyzed by paired <italic>t</italic>-test. (<bold>D</bold>) Comparison of Nef-positive cell frequencies in non-Env-specific (left) versus Env-specific (right) B cells in lymph nodes of persistently SIV-infected macaques (n = 6). Analyzed by paired <italic>t</italic>-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Machine learning-verified morphological gating of Nef-invaded B cells in vivo.</title><p>(<bold>A</bold>) Representative gating strategy plus schematic of inguinal lymph node Nef<sup>+</sup>CD19<sup>+</sup> B cells of an SIV<sub>mac239</sub>-infected rhesus macaque analyzed using ImageStreamX MK II imaging flow cytometry (R10-012, week 160 post-infection [p.i.]). First-step incorporation of Live/Dead staining gates out CD19<sup>+</sup> B cells staining positive for Nef potentially due to pre-experimental membrane permeation (e.g., image #246896, #248952, and #71859). Second-step dual gating for intracellular Nef signal pixel Haralick variance mean (H Variance mean, X-axis), a textural feature calculated from a gray-level co-occurrence matrix (GLCM) for each image representing adjacent pixel signal strength heterogeneity and Nef signal intensity threshold (Y-axis) gates out CD19<sup>+</sup> B cells showing potentially non-specific, strong intracellular binary clustered staining pixels for Nef deriving a large variance (X-axis), and/or cells stained overtly strong for Nef and hence becoming void for feasible image verification (high threshold) (Y-axis), both likely originating stochastically from post-experimental rupturing procedures including membrane permeation (e.g., image #18541). This two-step noise cancellation results in acquisition of a Live/Dead<sup>-</sup>-Nef signal Haralick variance mean<sup>lo</sup>-Nef signal intensity threshold<sup>lo</sup>-Nef<sup>+</sup>CD19<sup>+</sup> B-cell population (e.g., image #116318, #116250, and #132927) with a pericellular Nef<sup>int-lo</sup> staining, biologically concordant with Nef membrane anchoring, resembling Nef<sup>+</sup> cells experimentally generated in vitro and showed the highest score in IDEAS6.3 machine learning module scoring for segregation of typical void vs. valid images (upper right). This gating was implemented for counting and analysis of Env-specific B-cell Nef invasion in vivo (<xref ref-type="fig" rid="fig5">Figure 5</xref>). (<bold>B</bold>) Detection of contact-dependent Nef invasion from SIV-infected HSC-F CD4<sup>+</sup> T cells to cocultured Ramos B cells in vitro. One typical image of an intercellular conduit (SSC, purple) with Nef (green) protrusions from infected HSC-F cells to CD19<sup>+</sup> (red) Ramos B cells from two independent experiments are shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Cell contact-dependent B-cell invasion from infected cells in vitro</title><p>To understand cell-intrinsic properties enhancing B-cell Nef acquisition in vivo, we addressed in an in vitro coculture reconstitution how infected cell-to-B-cell Nef invasion takes place and how it is modulated. We performed imaging cytometry on a 12-hour coculture of SIV-disseminating HSC-F cells (reaching around 30% Nef-positivity at moment of coculture) with Ramos B cells, with or without modulators added throughout the coculture period (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, top left). In this coculture, there is no MHC-related interaction known to enhance T-cell/B-cell contact (<xref ref-type="bibr" rid="bib115">Wülfing et al., 1998</xref>). Machine learning-verified noise cancellation of fragmented signal acquisition (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, middle left) filtered reproducible images of Nef-positive HSC-F cells directly adhering to Ramos B cells within the doublet population (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, top to middle right). Importantly, addition of soluble, stimulation-competent antibodies against macaque CD3 enhanced adhesion of Nef<sup>+</sup> T cells to B cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, bottom center). In these doublets, we readily detected images of polarized Nef protrusion/injection from T cells to B cells (second column, filled wedges) as well as trogocytosed B-cell membranes (third column, open wedge), suggesting dynamic Nef acquisition by B cells. Changing centrifugation strengths upon coculture collection and staining (190 × <italic>g</italic> vs. 1200 × <italic>g</italic> and 600 × <italic>g</italic> vs. 1200 × <italic>g</italic>, respectively) shifted the tendency between enriched Nef<sup>+</sup> HSC-F-B-cell doublet versus singlet detection via CD3 stimulation, respectively (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, lower right).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Contact-dependent enhancement of B-cell Nef acquisition in reconstitution.</title><p>(<bold>A</bold>) Imaging flow cytometric analyses of stimuli-dependent enhancement of infected HSC-F cell adhesion to non-permissive CD19<sup>+</sup> Ramos B cells with the indicated gating (left). Cocultured doublet cells subjected to machine learning-verified filtration of fragmented signal acquisition (via gating Nef pixel signal contrast<sup>lo</sup>-Nef mean pixel per object<sup>hi</sup> cells) deriving typical images of infected HSC-F cell (Nef stain shown in pale blue pseudocolor) adhesion to Ramos cells (CD19 stain shown in purple pseudocolor) are shown. Analyzed by unpaired <italic>t</italic>-test for doublet formation in the unstimulated versus anti-CD3 monoclonal antibody (clone FN-18)-stimulated group. (<bold>B</bold>) Flow cytometric analyses of Nef-acquiring live CD19<sup>+</sup> Ramos B cells upon coculture with simian immunodeficiency virus (SIV)-infected HSC-F cells with or without the indicated stimuli. Analyzed by one-way ANOVA with Tukey’s post hoc multiple comparison tests. (<bold>C</bold>) Representative flow cytometric plot (left), histogram (middle), and pAkt Ser473 signal deviation in WT versus G63E Nef-acquiring CD20<sup>+</sup> primary B cells (six wells/control). Analyzed by unpaired <italic>t</italic>-test. Data represent pooled data of two experiments (<bold>A</bold>) or one of three (<bold>B, C</bold>) independent experiments with indicated number of replicates showing similar results.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig6-v1.tif"/></fig><p>Substantiated by the acquired images, an enhancement of live singlet Ramos B-cell Nef acquisition (% Nef<sup>+</sup> in total B cells) was also observed by CD3 stimulation in conventional flow cytometry (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). There was a similar enhancement when we added phytohemagglutinin (PHA), whereas phorbol-12-myristate-13-acetate (PMA)/ionomycin did not affect Nef acquisition by B cells. In a similar 72-hour static coculture with primary CD20<sup>+</sup> B cells, we detected recapitulation of the decreased B-cell pAkt Ser473 phosphorylation upon G63E Nef transfer compared to that of WT Nef (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), indicating that the Nef-G63E mutation can directly alleviate maturation inhibition in preferentially Nef-targeted Env-specific B cells.</p></sec><sec id="s2-7"><title>Enhanced Env-specific B-cell responses after PI3K-diminuting mutant selection</title><p>Finally, to assess in vivo B-cell quality in NAb inducers with Nef-G63E mutant selection, we examined peripheral SIV Env-specific IgG<sup>+</sup> B-cell responses comprising plasmablasts (PBs) and memory B cells (B<sub>mem</sub>). After excluding lineage-specific cells (T/NK/pro-B cells/monocytes/myeloid dendritic cells [DCs]/plasmacytoid DCs), we defined IgG<sup>+</sup> PBs as showing high replication (Ki-67<sup>+</sup>), post-activation (HLA-DR<sup>+</sup>), transcriptional switching for terminal differentiation (IRF4<sup>hi</sup>), and downregulated antigen surface binding (surface [s]Env<sup>lo</sup>-cytoplasmic [Cy]Env<sup>+</sup>) (<xref ref-type="bibr" rid="bib82">Nutt et al., 2015</xref>; <xref ref-type="bibr" rid="bib103">Silveira et al., 2015</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). NAb inducers showed significantly higher Env-specific IgG<sup>+</sup> PB responses around week 30 p.i., after Nef-G63E selection, compared to those in NAb non-inducers (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>). At 1 year, this difference became enhanced as a result of less pronounced decrease in Env-specific PB frequencies in the NAb inducers.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Enhanced simian immunodeficiency virus (SIV) Env-specific B-cell output up to neutralizing antibody (NAb) induction following Nef-G63E selection.</title><p>(<bold>A</bold>) Representative gating (R02-004, week 32 post-infection [p.i.]) of SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and plasmablasts (PBs). Two panels for PB gating are shown in lower resolution for visibility. B<sub>mem</sub> staining was performed separately and gating are merged with PB panels (first row, panels 2–4). (<bold>B</bold>) Changes in SIV Env gp140-specific PB frequencies in viremic NAb non-inducers (left, n = 12) and Nef-G63E-selecting NAb inducers (right, n = 6). Available samples of twelve viremic NAb non-inducers (including ten with ≥1-year survival) and six NAb inducers were tracked. In the right panel, the frequencies in NAb non-inducers are shown in background (gray) for comparison. (<bold>C</bold>) Comparison of Env gp140-specific PB frequencies between NAb non-inducers and inducers by Mann–Whitney <italic>U</italic> tests. In the right, the frequencies at NAb induction were compared with those at year 1 in NAb non-inducers with ≥1-year survival (n = 10). Bars: mean ± SD. (<bold>D</bold>) Left: vector chart of Env gp140-specific memory B cell (B<sub>mem</sub>) and PB levels. Legends for each animal correspond to the ones in (<bold>B</bold>). Right: NAb non-inducer vectors empirically define a polygonal GC output attractor area <italic>D<sub>n</sub></italic> (gray area surrounded with dotted lines) on which they converge by and beyond year 1 p.i. The NAb inducer vectors (shown up to the time of NAb induction) remained outside of <italic>D<sub>n</sub></italic>. At the moment of NAb induction they converged on a second GC output attractor area <italic>D<sub>i</sub></italic> (red area surrounded with dotted lines), mutually exclusive with <italic>D<sub>n</sub></italic> (p&lt;0.0001 by Fisher’s exact test on NAb inducer vector convergence frequency within <italic>D<sub>n</sub></italic>). Legends for year 1 p.i. in the NAb non-inducers and moment of NAb induction in the NAb inducers are specified.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Full gating strategy of SIV<sub>mac239</sub> Env gp140-specific B-cell responses.</title><p>Full gating (R02-004, week 32 p.i.) of SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and plasmablasts (PBs) shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>. For lineage-specific exclusion, CD10 was stained independently for B<sub>mem</sub>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88849-fig7-figsupp1-v1.tif"/></fig></fig-group><p>Simultaneous quantification of Env-specific PB and IgD<sup>-</sup>CD27<sup>+</sup>IgG<sup>+</sup> B<sub>mem</sub> responses allowed for an assessment of overall B-cell response quality by pair-wise analysis of Env-specific IgG<sup>+</sup> B<sub>mem</sub>/PB as a projection of germinal center (GC) output (<xref ref-type="bibr" rid="bib122">Zotos et al., 2010</xref>; <xref ref-type="fig" rid="fig7">Figure 7D</xref>, left). In this two-dimensional vector temporally plotting the frequency of B<sub>mem</sub> and PBs, vector protrusion toward the upper right represents higher gross GC output of antibody-forming cells (AFCs). In NAb non-inducers, all vectors converged on an empirically defined polygonal attractor area <italic>D<sub>n</sub></italic> (gray area surrounded with dotted lines in <xref ref-type="fig" rid="fig7">Figure 7D</xref>, right) at year 1 p.i. and beyond, describing that these NAb non-inducers failed to sustain Env-specific GC output. In contrast, the vectors were consistently tracked outside <italic>D<sub>n</sub></italic> in the NAb inducers with Nef-G63E (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). At the time of NAb induction, they converged on another upper-right GC output attractor area <italic>D<sub>i</sub></italic> (red area surrounded with dotted lines in <xref ref-type="fig" rid="fig7">Figure 7D</xref>, right) that is mutually exclusive with <italic>D<sub>n</sub></italic> (p&lt;0.0001 by Fisher’s exact test on NAb non-inducer/inducer vector distribution frequency within <italic>D<sub>n</sub></italic>). These suggest more robust virus-specific IgG<sup>+</sup> B-cell responses following Nef-G63E CD8<sup>+</sup> T-cell escape mutant selection, ultimately leading to NAb induction. The enhanced signature of cognate B cells was also an inverted pattern of impaired terminal differentiation of B-cell responses in APDS (<xref ref-type="bibr" rid="bib3">Al Qureshah et al., 2021</xref>).</p><p>Taken together, in the current model, Nef<sub>62-70</sub>-specific CD8<sup>+</sup> T-cell responses in persistently SIV<sub>mac239</sub>-infected macaques selected for an escape mutant, Nef-G63E, which displays attenuated aberrant Nef binding and ensuing drive of B-cell-inhibitory PI3K/mTORC2. Nef invasion of B cells in vivo occurred more preferentially in Env-specific B cells, suggesting diminution in Nef-mediated tonic dysregulation of B cells after mutant selection. These events conceivably predisposed to enhanced Env-specific B-cell responses and subsequent SIV<sub>mac239</sub>-specific NAb induction, altogether, in a manner reciprocal to human APDS-mediated immune dysregulation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we found that in macaques infected with an NAb-resistant SIV, selection of a CD8<sup>+</sup> T-cell escape <italic>nef</italic> mutant virus, Nef-G63E, precedes NAb induction. As a result, Nef binding-mediated drive of PI3K/mTORC2 in Env-specific B cells becomes attenuated, which in turn unleashes maturation of antiviral B-cell responses in vivo to induce NAbs. Importantly, this manifested through a pAkt deviation level more pronounced than WT versus germline <italic>PIK3CD</italic> gain-of-function mutation heterozygote mice recapitulating full human APDS phenotype (<xref ref-type="bibr" rid="bib6">Avery et al., 2018</xref>). Thus, the current Nef-G63E-associated B-cell/NAb phenotype likely occurs in a ‘reciprocal APDS-like’ manner. This proposition was enhanced based on the extension of immune cell-intrinsic Nef influence on cognate B cells (<xref ref-type="fig" rid="fig5">Figure 5</xref>), in addition to infected T cells. This work is, to our knowledge, the first to interlink a PI3K/mTORC2-modulating viral signature and enhanced B-cell/NAb responses in a viral infection model.</p><p>A link between viral T-cell escape and consequent immune modulation has been previously explored to some extent. For example, enhanced binding of mutant HIV-1 epitope peptide to inhibitory MHC-I on DCs impairs T cells (<xref ref-type="bibr" rid="bib58">Lichterfeld et al., 2007</xref>) and decreased CTL-mediated lymph node immunopathology can drive, and not inhibit, the production of LCMV-specific antibodies (<xref ref-type="bibr" rid="bib8">Battegay et al., 1993</xref>). Our results now evidence a new pattern of NAb responses that are bivalently shaped through viral interactions with both humoral and cellular immunity in AIDS virus infection. SIV<sub>mac239</sub> infection of macaques possessing MHC-I alleles associated with Nef-G63E mutation can be one unique platform to analyze virus–host interaction for B cell maturation leading to NAb induction. The interval between Nef-G63E mutant selection and NAb induction was variable in the NAb inducers, for which we did not obtain a clear explanation. This may be influenced by certain basal competitive balance between humoral versus cellular adaptive immunity (<xref ref-type="bibr" rid="bib90">Recher et al., 2007</xref>), as observed in certain vaccination settings (<xref ref-type="bibr" rid="bib87">Querec et al., 2009</xref>).</p><p>The current Nef-G63E phenotype identified here adds yet another aspect to the wealth of evidence documenting the multifaceted impact of Nef in HIV/SIV infection (<xref ref-type="bibr" rid="bib51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="bib23">Gauduin et al., 2006</xref>; <xref ref-type="bibr" rid="bib107">Stolp et al., 2012</xref>). Based on our data, the current phenotype differed from decreased replication-related properties or generalized amelioration in immune impairment such as those of delta-Nef HIV/SIV (<xref ref-type="bibr" rid="bib51">Kirchhoff et al., 1995</xref>; <xref ref-type="bibr" rid="bib43">Johnson et al., 1997</xref>; <xref ref-type="bibr" rid="bib23">Gauduin et al., 2006</xref>; <xref ref-type="bibr" rid="bib22">Fukazawa et al., 2012</xref>). The SIV Nef N-terminal unstructured region comprising Nef-G63E is not conserved in HIV-1 (<xref ref-type="bibr" rid="bib97">Schindler et al., 2004</xref>), and beyond this model study it remains to be addressed whether a mutant HIV-1 with a similar immunosignaling-related phenotype can be obtained and how much lentiviral conservation exists for such interactions. Analysis of cognate B-cell maturation on cohort basis (<xref ref-type="bibr" rid="bib31">Hau et al., 2022</xref>) may potentially assist this approach.</p><p>Preferential Nef transfer to Env-specific B cells (<xref ref-type="fig" rid="fig5">Figure 5</xref>) suggests potential involvement of polarized perturbation in cognate immune cells in vivo, which was best depicted for preferential infectivity of HIV-specific CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib17">Douek et al., 2002</xref>) and HIV condensation to the interface of DC-T-cell contacts (<xref ref-type="bibr" rid="bib68">McDonald et al., 2003</xref>). As cognate MHC class II interactions (<xref ref-type="bibr" rid="bib115">Wülfing et al., 1998</xref>; <xref ref-type="bibr" rid="bib25">Gitlin et al., 2014</xref>) regularly occur between HIV/SIV-specific CD4<sup>+</sup> T cells and Env-specific B cells in GCs, dysregulation of Env-specific B cells may well result from hijacking of cognate T-cell/B-cell interactions by the virus. Enhanced T-cell attachment and transfer of Nef to B cells by TCR stimulation (<xref ref-type="fig" rid="fig6">Figure 6</xref>) may override constraints of infection-mediated CD4<sup>+</sup> T-cell cytoskeletal impairment (<xref ref-type="bibr" rid="bib12">Campbell et al., 2004</xref>; <xref ref-type="bibr" rid="bib44">Jolly et al., 2004</xref>; <xref ref-type="bibr" rid="bib106">Stolp et al., 2009</xref>), particularly by antagonizing reduced motility (<xref ref-type="bibr" rid="bib107">Stolp et al., 2012</xref>), resulting in in vivo ‘filtering’ of enhanced cognate CD4<sup>+</sup> T-cell interaction with cognate B cells. Interestingly, Tfh cells that bear trogocytosed CD20 and are positive for viral DNA appear in vivo during SIV infection and increase when infection progresses (<xref ref-type="bibr" rid="bib93">Samer et al., 2023</xref>). This is consistent with our data that suggest occurrence of contact-dependent, polarized interactions facilitating Nef transfer to cognate B cells.</p><p>The major in vivo readout of this study is autologous neutralization of a highly difficult-to-neutralize SIV strain, which is different from HIV-specific broadly neutralizing antibodies (bNAbs). Importantly, however, obtained signatures of enhanced IgG<sup>+</sup> Env-specific AFC and B cells (class switch/terminal differentiation) and virus neutralization (hypermutation) in our model are indicative of elevated activity of activation-induced cytidine deaminase (AID), the canonical positive driver of B-cell fate. Thus, we reason that findings in this study have a strong conceptual continuity with bNAb regulation by AID in HIV infection.</p><p>Our results extracted an in vivo link between a decrease in aberrant Nef-PI3K/mTORC2 interaction and major enhancement in B-cell responses. The relationship is reciprocal to immunogenetic mechanisms of human PI3K gain-of-function mutations, resulting in APDS with multiply impaired antiviral B-cell responses. APDS occurs from germline mutations in leukocyte-intrinsic p110δ catalytic subunit-coding <italic>PIK3CD</italic> or the ubiquitous p85α regulatory subunit-coding <italic>PIK3R1</italic>. In both cases, the mutations cause residue substitutions, resulting in class IA PI3K gain of function (<xref ref-type="bibr" rid="bib16">Dornan et al., 2017</xref>). Hyperactivated PI3K interferes with cognate B cells in an immune cell-intrinsic manner, leading to impaired B-cell class switching and resultant susceptibility against various infections (<xref ref-type="bibr" rid="bib4">Angulo et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Lucas et al., 2014</xref>; <xref ref-type="bibr" rid="bib13">Coulter et al., 2017</xref>). In the current work, we conversely document a decrease in virally induced tonic PI3K drive, enhanced IgG class-switched cognate B-cell responses and NAb induction against a notably difficult-to-neutralize SIV. The exact hierarchy of binding between Nef and PI3K/mTORC2 components (including PI3K isoforms) and its alteration by Nef-G63E mutation remains to be investigated. Yet PI3Kp85 showed the strongest Nef-binding index in PLA assay (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) presumably because of the SH3-binding PxxP domain in Nef, which binds the SH3 domain of PI3Kp85 (<xref ref-type="bibr" rid="bib92">Rickles et al., 1994</xref>). Decreased binding of Nef to its canonical target PI3Kp85 may precipitate into attenuated interactions of Nef with quintuple PI3K/mTORC2, resulting in fragile downstream Akt signaling. Such domino-triggering is also observed in APDS patients, from gain-of-function mutant p85 to p110 (<xref ref-type="bibr" rid="bib16">Dornan et al., 2017</xref>), which similarly illustrates the fine-tuned nature of the PI3K/mTORC2/Akt signaling pathway.</p><p>A limitation of this study is the use of retrospective samples, posing constraints for detecting exact temporal changes in tonic viral B-cell perturbation. Related with this, it was not attainable to optimally time the sampling of lymph node cells in animals belonging to the subgroup of interest. Certain plasma and cellular samples were also unavailable in differing experiments. While partially addressed in in vitro reconstitution, much remains to be investigated for the observed polarity of Env-specific B-cell perturbation in vivo. Similarly, influence of the Nef-G63E phenotype on CD4<sup>+</sup> T cells in vivo and its consequence on B-cell modulation remains largely elusive, and in the current work we focused mainly on the molecular properties of the NAb-correlating Nef-G63E mutant strain. HIV/SIV infection uniquely shows a biphasic Tfh dysregulation of acute-phase destruction <xref ref-type="bibr" rid="bib67">Mattapallil et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Moukambi et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Moukambi et al., 2019</xref> followed by dysregulated chronic-phase hyper-expansion (<xref ref-type="bibr" rid="bib60">Lindqvist et al., 2012</xref>; <xref ref-type="bibr" rid="bib85">Petrovas et al., 2012</xref>; <xref ref-type="bibr" rid="bib14">Cubas et al., 2013</xref>; <xref ref-type="bibr" rid="bib117">Xu et al., 2016</xref>). Further studies are therefore warranted to uncover how the Nef mutant, which is proapoptotic and displays ameliorated PI3K drive, influences Tfh responses at different phases of the infection. Gain-of-function mutations in PI3K-encoding genes appear to affect B cells more strongly (<xref ref-type="bibr" rid="bib5">Asano et al., 2018</xref>). Nonetheless, it is noteworthy that they also evoke basal dysregulation in peripheral CD4<sup>+</sup> T cells, which locally recapitulates dysregulation and death of HIV/SIV-infected CD4<sup>+</sup> T cells, highlighting the importance of PI3K-mediated signaling in HIV/SIV infection. In any event, we surmise that specific animal models like the current one help to depict a temporal cascade of in vivo events leading to NAb induction, assisting human immunology. As an extension of this study extracting the NAb-involved molecular axis, manipulation/reconstitution experiments shall be designed.</p><p>In conclusion, we demonstrated in a non-human primate AIDS model that NAb induction against a difficult-to-neutralize SIV strain occurs after selection of a CD8<sup>+</sup> T-cell escape variant with a reduced ability to drive excess PI3K/mTORC2 signaling. These results collectively offer an example of how NAb responses against immunodeficiency viruses can be shaped by both wings of adaptive immune pressure. Given the key role for Nef-mediated perturbation of PI3K/mTORC2 in NAb resistance, immune cell-intrinsic PI3K/mTORC2 manipulation may offer a new possibility to harness antiviral NAb responses. As human IEIs are increasingly becoming discovered with various immune-perturbing phenotypes and inheritance patterns (<xref ref-type="bibr" rid="bib39">Jauch et al., 2023</xref>), search of other types of analogies between viral immune dysregulations and human IEIs may fuel the discovery of novel targets to modulate and harness immune responses in translational settings.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Materials availability</title><p>This study did not generate new unique reagents.</p></sec><sec id="s4-2"><title>Rhesus macaques retrospectively utilized for samples</title><p>In total, 70 Burmese rhesus macaques (<italic>Macaca mulatta</italic>) (57 males and 13 females) were retrospectively analyzed in this study. Experiments were previously carried out (<xref ref-type="bibr" rid="bib66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="bib37">Ishii et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="bib101">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Iwamoto et al., 2014</xref>; <xref ref-type="bibr" rid="bib110">Terahara et al., 2014</xref>) at the Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), with the help of the Corporation for Production and Research of Laboratory Primates and the Institute for Frontier Life and Medical Sciences, Kyoto University (IFLMS-KU) after approval by the Committee on the Ethics of Animal Experiments of NIBIOHN and IFLMS-KU under the guidelines for animal experiments at NIBIOHN, IFLMS-KU, and National Institute of Infectious Diseases in accordance with the ‘<ext-link ext-link-type="uri" xlink:href="https://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf">Guidelines for Proper Conduct of Animal Experiments</ext-link>’ established by Science Council of Japan. The experiments were in accordance with the ‘<ext-link ext-link-type="uri" xlink:href="https://royalsociety.org/news-resources/publications/2006/weatherall-report/">Weatherall report on the use of non-human primates in research</ext-link>’ recommendations. Animals were housed in adjoining individual primate cages, allowing them to make sight and sound contact with one another for social interactions, where the temperature was kept at 25°C with light for 12 hours per day. Animals were fed with apples and commercial monkey diet (Type CMK-2, Clea Japan, Inc). Blood collection and virus challenge were performed under ketamine anesthesia.</p></sec><sec id="s4-3"><title>Cells and viruses</title><p>MT4-R5 cells were maintained in RPMI1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Clontech) and antibiotics. HSC-F cells (cynomolgus CD4<sup>+</sup> T-cell line) and HSR5.4 cells (rhesus macaque CD4<sup>+</sup> T-cell line) were maintained in RPMI1640 (Invitrogen) supplemented with 10% FBS (Clontech), human IL-2 (10 IU/ml, Roche), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Invitrogen), and 2-mercaptoethanol (Gibco). SIV<sub>mac239</sub> molecular clone derivative was generated by mutagenesis PCR (Agilent Technologies) using the primers listed. For virus preparation, COS-1 cells were transfected with pBR<sub>mac239</sub> proviral DNA using FuGENE 6 (Promega). At 48 hours post-transfection, culture supernatants were harvested, centrifuged, and filtered through a 0.45 μm pore-size filter (Merck Millipore). To titrate infectivity, prepared viruses were serially diluted and infected on HSC-F cells in 96-well plates (Falcon) in quadruplicate. At 10 days p.i., the endpoint was determined using SIV p27 antigen ELISA kit (ABL), and virus infectivity was calculated as the 50% tissue culture infective dose (TCID<sub>50</sub>) according to the Reed–Muench method.</p></sec><sec id="s4-4"><title>Identification of SIV<sub>mac239</sub>-NAb inducers</title><p>Burmese rhesus macaques previously challenged with the highly pathogenic molecular clone virus SIV<sub>mac239</sub> (n = 70) were retrospectively examined approximately up to 2 years for their plasma NAb profiles. Animals were challenged intravenously with 1000 TCID<sub>50</sub> of SIV<sub>mac239</sub>. In the current study, virological and immunological profiles were compared between the newly identified NAb inducers (n = 9) and representative NAb non-inducers (n = 19). Sex distribution of the NAb inducers (eight males and one female) did not significantly differ with the total non-inducers (49 males and 12 females, p=0.99 by Fisher’s exact test). These NAb non-inducers and eight NAb inducers except R06-032 were previously partially reported for their plasma viral loads (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Iwamoto et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). MHC-I haplotypes and alleles were determined by reference strand-mediated conformation analysis, PCR-SSP (PCR amplification utilizing sequence-specific priming), and cloning as described (<xref ref-type="bibr" rid="bib76">Naruse et al., 2010</xref>). MHC-I binding prediction was made on April 27, 2013, using the IEDB analysis resource NetMHCpan tool (<xref ref-type="bibr" rid="bib34">Hoof et al., 2009</xref>). Alleles of interest in the study have been previously identified in macaques (<xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="bib18">Evans et al., 1999</xref>; <xref ref-type="bibr" rid="bib99">Sette et al., 2012</xref>). Macaques R06-032, R03-015, R01-010, and R05-010 received a prime-boost vaccination (<xref ref-type="bibr" rid="bib66">Matano et al., 2004</xref>) composed of a DNA prime/intranasal Sendai virus vector expressing SIV<sub>mac239</sub> Gag (SeV-Gag). R03-015, R06-019, R06-038, and R10-001 received 300 mg of non-specific rhesus IgG at day 7 post-SIV<sub>mac239</sub> challenge as an experimental control in our previous reports (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>).</p></sec><sec id="s4-5"><title>Plasma viral load quantitation</title><p>Plasma viral RNA samples were extracted with High Pure Viral RNA kit (Roche Diagnostics). Serial fivefold sample dilutions were amplified in quadruplicate by reverse transcription and nested PCR using SIV<sub>mac239</sub> <italic>gag</italic>-specific primers to determine end point via the Reed–Muench method as described previously (<xref ref-type="bibr" rid="bib66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>). The lower limit of detection is approximately 400 viral RNA copies/ml plasma. Viral loads have been previously partially reported (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib81">Nomura et al., 2012</xref>; <xref ref-type="bibr" rid="bib109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Iwamoto et al., 2014</xref>).</p></sec><sec id="s4-6"><title>SIV<sub>mac239</sub>-specific neutralization assay</title><p>NAbs were titrated as described (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>). Serial twofold dilutions of heat-inactivated plasma or polyclonal IgG affinity-purified with Protein G Sepharose 4 Fast Flow (GE Healthcare) from heat-inactivated and filtered plasma were mixed with 10 TCID<sub>50</sub> of SIV<sub>mac239</sub> at a 1:1 ratio (5 μl:5 μl) in quadruplicate. After 45-minute incubation at room temperature, the 10 μl mixtures were added into 5 × 10<sup>4</sup> MT4-R5 cells/well in 96-well plates. Progeny virus production in day 12 culture supernatants was examined by SIV p27 ELISA (ABL) to determine 100% neutralizing endpoint. The lower limit of titration is 1:2. Neutralization in three out of four wells at a dilution of 1:2 is defined as marginally NAb-positive (&lt;1:2). Results were comparable when the same assay was performed with macaque HSC-F cells (<xref ref-type="bibr" rid="bib2">Akari et al., 1996</xref>) as targets. NAb inducers R01-012, R02-004, R01-010, R02-007, and NAb non-inducer R01-011 were previously partially reported for their NAb titers measured with the same method using MT4 cells as targets (<xref ref-type="bibr" rid="bib46">Kawada et al., 2007</xref>), which derived comparable results. For the assessment of neutralizing activity in IgG, SIV<sub>mac239</sub>-specific IgGs purified from pools of plasma with SIV<sub>mac239</sub>-specific NAb titers were obtained from each animal as described (<xref ref-type="bibr" rid="bib119">Yamamoto et al., 2007</xref>). After complement heat inactivation at 56°C, 30 minutes, and 0.45 μm filtration, IgGs were purified by Protein G Sepharose 4 Fast Flow (GE Healthcare) and concentrated by Amicon Ultra 4, MW 50,000 (Millipore) to 30 mg/ml and similarly examined for their 10 TCID<sub>50</sub> SIV<sub>mac239</sub> killing titers on MT4-R5 cells.</p></sec><sec id="s4-7"><title>SIV Env-specific IgG ELISA and immunoblotting</title><p>Plasma Env-specific IgG titers were measured as described (<xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>). SIV<sub>mac251</sub> Env gp120 (ImmunoDiagnostics) were coated on 96-well assay plates (BD) at 1000 ng/ml (100 μl/well). Wells were prewashed with phosphate-buffered saline (PBS), blocked with 0.5% bovine serum albumin (BSA)/PBS overnight, and plasma samples were incubated at a 1:20 dilution (5 μl:95 μl) for 2 hours. Wells were washed with PBS and SIV Env-bound antibodies were detected with a horseradish peroxidase (HRP)-conjugated goat anti-monkey IgG (H+L) (Bethyl Laboratory) and SureBlue TMB 1-Component Microwell Peroxidase Substrate (KPL). Absorbance at 450 nm was measured. Samples from week 0 pre-challenge and month 3, month 6, and year 1 post-challenge were assessed in duplicate. Week 0 average values were subtracted from the corresponding later time point values for calibration. For immunoblotting, SIV virion-specific IgGs in plasma were detected with a SIV<sub>mac239</sub>-cross-reactive western blotting system (ZeptoMetrix). In the NAb non-inducers, samples from those close to rapid progression (euthanized due to AIDS progression within approximately 1 year) known for low plasma anti-SIV reactivity (<xref ref-type="bibr" rid="bib33">Hirsch et al., 2004</xref>; <xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>) were not included.</p></sec><sec id="s4-8"><title>Sequencing</title><p>Sequencing was performed as described (<xref ref-type="bibr" rid="bib66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>). Viral cDNA fragments spanning from nt (nucleotide) 4829 to nt 7000, nt 6843 to nt 8831, and nt 8677 to nt 10196 in SIV<sub>mac239</sub> (GenBank accession number MM33262) covering SIV <italic>env</italic> and <italic>nef</italic> were amplified from plasma viral RNA by nested RT-PCR using Prime-Script one-step RT-PCR kit v2 (TaKaRa) and KOD-Plus v2 (Toyobo). PCR products were either directly sequenced or subcloned with a TOP10-transforming TOPO blunt-end cloning system (Invitrogen). Sequencing was performed using dye terminator chemistry with an ABI 3730 DNA sequencer (Applied Biosystems). On average, 15 clones were obtained per sample and 20 clones were assessed when <italic>nef</italic> mutations of interest in early time points were subdominant.</p></sec><sec id="s4-9"><title>SIV<sub>mac239</sub>-specific CD8<sup>+</sup> T-cell responses</title><p>Virus-specific CD8<sup>+</sup> T-cell frequencies were measured as described (<xref ref-type="bibr" rid="bib66">Matano et al., 2004</xref>; <xref ref-type="bibr" rid="bib36">Iseda et al., 2016</xref>). Peripheral blood mononuclear cells (PBMCs) were cocultured for 6 hours with autologous herpesvirus papio-immortalized B lymphoblastoid cell lines (B-LCLs) pulsed with Nef peptides (Sigma-Aldrich Japan) at 1 μM concentration or as indicated otherwise under GolgiStop (monensin, BD) presence. Intracellular gamma interferon (IFN-γ) staining was performed using Cytofix/Cytoperm kit (BD) and the following conjugated anti-human monoclonal antibodies (mAbs): anti-CD4-FITC (M-T477, BD Pharmingen), anti-CD8-PerCP (SK1, BD Biosciences), anti-CD3-APC (SP34-2, BD Pharmingen), and anti-IFN-γ-PE (4S.B3, BioLegend). Specific CD8<sup>+</sup> T-cell frequencies were determined by subtracting nonspecific IFN-γ<sup>+</sup> CD8<sup>+</sup> T-cell frequencies from those after peptide-specific stimulation; frequencies beneath 100 cells/million PBMCs were considered negative. Cells acquired by FACS Canto II (BD) were analyzed using FACS Diva (BD) and FlowJo (Treestar). Approximately 1 × 10<sup>5</sup> PBMCs were gated per test.</p></sec><sec id="s4-10"><title>Nef-mediated signaling perturbation analysis</title><p>Virus supernatants obtained from COS-1 cells after transfection with WT or mutant SIV<sub>mac239</sub> molecular clones were used for infection of CD4<sup>+</sup> T-cell lines, cynomolgus macaque-derived HSC-F, and rhesus macaque-derived HSR5.4 (<xref ref-type="bibr" rid="bib2">Akari et al., 1996</xref>). QuikChange II XL site-directed mutagenesis kit (Agilent Technologies) was used to construct mutant SIV<sub>mac239</sub> molecular clones possessing <italic>nef</italic> mutations Nef-G63E (G-to-A mutation at nt 9520) and Nef-G63R (G-to-A mutation at nt 9519) from the WT SIV<sub>mac239</sub> molecular clone (<xref ref-type="bibr" rid="bib48">Kestler et al., 1991</xref>) (nt number from GenBank accession number M33262). Cells (1 × 10<sup>5</sup> cells/well in U-bottomed 96-well culture plates [BD]) were infected with WT or mutant SIV<sub>mac239</sub> cultured in RPMI-1640 medium supplemented with 10% FBS for indicated periods at MOI 0.1 (intracellular signaling analysis) or 0.001 (supernatant analysis). Culture supernatants were subjected to measurement of SIV capsid p27 concentrations by ELISA. Harvested cells were fixed and permeabilized with Cytofix/Cytoperm kit, washed twice, and subjected to immunostaining. The following antibodies were used; anti-SIV<sub>mac251</sub> Gag p27 mAb (ABL) manually conjugated with Alexa 647 (Life Technologies), anti-SIV<sub>mac251</sub> Nef mAb (clone 17, epitope peptide corresponding to SIV<sub>mac239</sub> Nef 71–80 not including the residue G63: Thermo Fisher Scientific/Pierce) manually conjugated with Alexa 488 or Alexa 647, anti-human CD3-APC-Cy7 (SP34-2, BD Pharmingen), anti-human CD4-PerCP (L200, BD Pharmingen), anti-human HLA-ABC-FITC (G46-2.6, BD Pharmingen), anti-human CXCR4-APC (12G5, BioLegend), BST2-Alexa 647 (RS38E, BioLegend), Alexa 488-conjugated anti-phospho-Akt (Ser473) (D9E, CST), and Alexa 488-conjugated anti-phospho-Akt (Thr308) (C31E5E, CST). Cells acquired by FACS Canto II were analyzed using FACS Diva and FlowJo. Approximately 5 × 10<sup>4</sup> cells were gated for each test.</p></sec><sec id="s4-11"><title>Ferritin ELISA</title><p>Plasma ferritin levels in NAb inducers and control animals were analyzed using monkey ferritin sandwich ELISA kit (LS Bio) according to the manufacturer’s instructions.</p></sec><sec id="s4-12"><title>PI3K stimulation assay</title><p>5 × 10<sup>4</sup> HSC-F cells were infected with WT or Nef-G63E mutant SIV<sub>mac239</sub> at MOI 0.2 and cultured for 1 day in medium supplemented with 10% (normal), 1% (1/10 starvation), or 0.1% (1/100 starvation) FBS. For ligand stimulation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>), cells at the end of 1-day culture were pulsed for 20 minutes with 40 ng/ml of recombinant human IFN-γ (Gibco/Thermo Fisher Scientific), 100 IU/ml of recombinant human IL-2 (Roche Diagnostics), or 10 μg/ml of SIV<sub>mac251</sub> Env gp130 (ImmunoDx). Cells were intracellularly stained using Cytofix/Cytoperm kit with anti-SIV<sub>mac251</sub> Nef mAb or anti-SIV<sub>mac251</sub> p27 mAb manually conjugated to Alexa 647 and PE-conjugated anti-human phospho-Akt (Ser473) (D9E, CST) or Alexa 488-conjugated anti-human phospho-Akt (Ser473). Cells acquired by FACS Canto II were analyzed using FACS Diva and FlowJo. Approximately 7 × 10<sup>4</sup> HSC-F cells were gated per test.</p></sec><sec id="s4-13"><title>Transcriptome analysis</title><p>Total RNAs were extracted using RNeasy Plus Mini kit (QIAGEN) from 2 × 10<sup>6</sup> HSC-F cells 1 day after infection with WT or Nef-G63E mutant SIV<sub>mac239</sub> at MOI 5. Negative control RNA samples were extracted from 2 × 10<sup>6</sup> uninfected HSC-F cells after culture with the same condition. Three sets of experiments were performed. Total RNA samples were subjected to a quality control (QC) analysis using an Agilent 2100 Bioanalyzer. The obtained amounts of total RNAs were 12.37 ± 0.39 (uninfected), 8.80 ± 0.44 (WT), and 9.02 ± 0.17 (Nef-G63E) μg (p=0.66 for WT vs. Nef-G63E by unpaired <italic>t</italic>-test). In all samples, two bands of 18S and 28S rRNA were confirmed and the RNA integrity number (RIN) was 10. 500 ng of total RNA samples were processed with GeneChip WT Plus reagent (Affymetrix/Thermo Fisher Scientific) to produce 150 μl of fragmented and labeled cDNA samples. These were incubated with a Human Gene 2.0 ST Array (Affymetrix/Thermo Fisher Scientific) for 16 hours, 60 rpm at 45°C using GeneChip hybridization oven 645 (Affymetrix/Thermo Fisher Scientific). Results were scanned with GeneChip Scanner 3000 7G (Affymetrix/Thermo Fisher Scientific) and processed with Affymetrix Expression Console Software (Affymetrix/Thermo Fisher Scientific) according to the manufacturer’s instructions. Expression values were normalized by the RMA method. Genes above mean background expression within the cognate sample and showing significant difference between WT and Nef-G63E SIV (p&lt;0.05 via unpaired <italic>t</italic>-test for log<sub>2</sub>-transformed values, 768 candidates) were determined. Akt-related genes exhibiting a change of approximately 10% or more were representatively extracted and manually aligned by the authors.</p></sec><sec id="s4-14"><title>Peripheral CD4<sup>+</sup> T-cell surface staining</title><p>Cryopreserved/thawed PBMCs were stained for 30 minutes at 4°C with the following reagents or conjugated anti-human mAbs: Live/Dead Aqua (Life Technologies), anti-CD4-PerCP (L200, BD Pharmingen), anti-CD8-APC-Cy7 (RPA-T8, BD Pharmingen), anti-CD3-Alexa 700 (SP34-2, BD Pharmingen), anti-CD95-PE-Cy7 (DX2, eBioscience), anti-CXCR5-PE (87.1, eBioscience), anti-PD-1-Brilliant Violet 421 (EH12.2H7, BioLegend), and anti-CXCR3-Alexa 488 (G025H7, BioLegend). Cells acquired by FACS LSRII Fortessa (BD) were analyzed using FACS Diva and FlowJo. Approximately 1.5 × 10<sup>5</sup> PBMCs were gated per test.</p></sec><sec id="s4-15"><title>Proximity ligation assay</title><p>A flow cytometry-based arrangement of PLA (<xref ref-type="bibr" rid="bib7">Avin et al., 2017</xref>) was performed to quantitatively assess Nef binding to candidate interacting molecules. 1 × 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.05 in U-bottomed plates and permeated with Cytofix/Perm kit (BD Biosciences). After two washes, they were resuspended in 0.5% BSA/PBS for the prevention of experimental procedure-related loss and stained with mouse anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) or mouse IgG1 isotype control mAb (P3.6.2.8.1, Abcam) in combination with either of the following rabbit antibodies: anti-GβL (86B8, CST), anti-mTOR (7C10, CST), polyclonal anti-human PI3K p85 (Merck Millipore), anti-PI3 Kinase p110α (C73F8, CST), or rabbit IgG1 isotype control mAb (DA1E, CST). Antibody-stained cells were subsequently probed with Duolink In Situ PLA Probe anti-mouse PLUS and anti-mouse MINUS probes (Sigma/Merck). Next, they were detected for intermolecular binding using Duolink flow PLA detection kit (Green) (Sigma/Merck) with a reaction time of 100 minutes for post-mouse/rabbit probe linking amplification. Finally, these PLA-subjected cells were additionally stained with anti-SIV<sub>mac251</sub> Gag p27 mAb manually conjugated with Alexa 647 and anti-CD4-PerCP for 20 minutes at 4°C. Cells acquired by FACS Canto II were analyzed using FACS Diva and FlowJo. Approximately 1 × 10<sup>5</sup> cells were gated per test. Binding index (Y-axis) was calculated by deriving the deviation from the summation of: {baseline P: (MFI of background reaction with mouse isotype control/rabbit isotype control) + anti-Nef antibody-derived background Q: [(MFI of reaction with mouse anti-Nef/rabbit isotype control) – (MFI of background reaction with mouse isotype control/rabbit isotype control)]+anti-binding partner antibody-derived background R:[(MFI of reaction with mouse isotype control/rabbit anti-binding partner molecule) – (MFI of background reaction with mouse isotype control/rabbit isotype control)]}.</p></sec><sec id="s4-16"><title>Co-immunoprecipitation analysis</title><p>1 × 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.05 in U-bottomed plates in quadruplicate for each SIV strain for 3 days and pooled for each for acquiring cell pellets. These pellets were lysed with Capturem IP &amp; Co-IP Kit lysis buffer (Takara), and portions for each were immunoprecipitated by anti-Sin1 mAb (D7G1A, CST) (1:50 dilution, 20 minutes, room temperature). Spin column membrane-bound immunoprecipitates were obtained by centrifugation with Capturem IP &amp; Co-IP Kit (Clontech/Takara). Whole-cell lysates and Sin1-immunoprecipitated products were subjected to SDS-polyacrylamide gel electrophoresis separation on a Mini Protean TGX 4–15% gel (Bio-Rad) and transferred to a Immun-Blot PVDF membrane (Bio-Rad). Immunoblotting was performed by mouse anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) primary antibody probing (1:1000 dilution, 18 hours, 4°C) and Mouse TrueBlot ULTRA anti-mouse Ig HRP (eB144, Rockland Immunochemicals) secondary antibody incubation (1:1000 dilution, 30 minutes, room temperature). Nef-specific bands in infected controls were visualized by enhanced chemiluminescence using SuperSignal West Pico PLUS (Thermo Fisher Scientific). Bands auto-detectable using Image Lab software (Bio-Rad) were analyzed for signal intensities. Uncropped images are provided as supplementary data.</p></sec><sec id="s4-17"><title>Cell death assay</title><p>Infected cell apoptosis was measured by methods previously described (<xref ref-type="bibr" rid="bib39">Jauch et al., 2023</xref>). 1 × 10<sup>5</sup> HSC-F cells were infected with SIV<sub>mac239</sub> at MOI 0.1 in U-bottomed plates (six wells/control) for each SIV strain for 3 days. These cells were stained with CD4-FITC (M-T477, BD Pharmingen) for 15 minutes at room temperature, washed once, and next stained with APC Annexin V (BioLegend) in Annexin V Binding Buffer (BioLegend) for 20 minutes at room temperature. Stained reactions were then diluted fivefold with Annexin V Binding Buffer and subjected to analysis. Cells acquired by FACS Lyric were analyzed using FACS Suite and FlowJo. Approximately 1 × 10<sup>4</sup> HSC-F cells were gated per test.</p></sec><sec id="s4-18"><title>Quantitative in vivo imaging flow cytometry</title><p>Cryopreserved/thawed lymph node cells (LNCs) from several persistently SIV-infected macaques used in previous experiments (<xref ref-type="bibr" rid="bib75">Nakane et al., 2013</xref>; <xref ref-type="bibr" rid="bib109">Takahashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Iwamoto et al., 2014</xref>) were seeded in V-bottomed 96-well plates (Nunc) and blocked with 25 μg/ml of anti-human CD4 (clone L200: BD) in 100 μl volume for 15 minutes at 4°C. After three washes, they were stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. Cells were then stained with anti-CD19-PC5.5 (J3-119, Beckman Coulter), Live/Dead Aqua (Invitrogen), and streptavidin-APC-Cy7 (BioLegend) for 30 minutes at 4°C. After two washes, cells were processed with Cytofix/Cytoperm kit (BD) for 20 minutes at 4°C, washed twice, and next intracellularly stained with PE-conjugated anti-human phospho-Akt (Ser473) (D9E, CST) and anti-SIV<sub>mac251</sub> Nef mAb (clone 17, Thermo Fisher Scientific/Pierce) manually conjugated with Alexa 488 or mouse IgG1 isotype control mAb (P3.6.2.8.1, Abcam) for 30 minutes at 4°C. After final two washes, cells were suspended in 0.8% PFA/PBS. All centrifugations for washing (1200 × <italic>g</italic>, 2 minutes) were performed at 4°C. Cells were subjected to image acquisition with Image Stream X MKII imaging flow cytometer (Amnis/Merck Millipore/Luminex) and analyzed with IDEAS 6.3 software (Amnis/Merck Millipore/Luminex). Approximately 5 × 10<sup>5</sup> LNCs were acquired for analyses (<xref ref-type="fig" rid="fig5">Figure 5</xref>). A custom-implemented linear discriminant analysis-based machine learning module (Luminex) was utilized for verifying candidate Nef staining signal-related secondary parameters (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>) for their efficacy of target population separation.</p></sec><sec id="s4-19"><title>B-cell Nef invasion in vitro assay</title><p>For Nef invasion assay, 5 × 10<sup>4</sup> HSC-F cells were infected at MOI 1 for 48 hours. These were then additionally cocultured with 7.5 × 10<sup>4</sup> Ramos B cells for 12 hours with or without addition of macaque T cell-stimulating anti-CD3 antibody (FN-18, Abcam) at 1 μg/ml. Cells were double-stained with Alexa 488-conjugated mouse anti-Nef (clone 17: Thermo Scientific/Pierce) and anti-CD19-PC-5.5 (J3-119, Beckman Coulter). For graphical visualization (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), interacting Nef<sup>+</sup> infected cell-invaded B cell doublet images acquired with ImageStream X MKII (Amnis/Merck Millipore) were analyzed using IDEAS 6.3 (Amnis/Merck Millipore/Luminex) with the defined noise-cancelling gating (via gating Nef pixel signal contrast<sup>lo</sup>-Nef mean pixel per object<sup>hi</sup> cells). For Nef invasion modulation verification on conventional flow cytometry, the aforementioned culture condition was similarly used. Anti-CD3 antibody (FN-18, Abcam) addition at 1 μg/ml and phorbol 12-myristate 13-acetate (PMA, Sigma) plus ionomycin (Sigma) addition (10 ng/ml and 50 ng/ml, respectively) were evaluated. Cells were stained with Alexa 647-conjugated mouse anti-Nef (clone 17: Thermo Scientific/Pierce), anti-CD19-PC-5.5 (J3-119, Beckman Coulter), anti-human phospho-Akt (Ser473)-Alexa 488 (D9E, CST), and Live/Dead Near-IR (Invitrogen) for dead cell exclusion. Dead cell frequencies were less than 3%. For viral phenotype evaluation, 1 × 10<sup>5</sup> HSC-F cells (surface CD40L<sup>+</sup>) were pre-infected at MOI 0.2 with WT or Nef-G63E mutant SIV<sub>mac239</sub> 6 hours before coculture. 1.5 × 10<sup>5</sup> CD20<sup>+</sup> B cells, positively selected from fresh PBMCs of uninfected rhesus macaques via anti-CD20 microbeads (Miltenyi Biotec), were cocultured with these HSC-F cells at an E:T ratio of 2:3 for 3 days in the presence of 40 ng/ml carrier-free recombinant human IL-4 (R&amp;D Systems). Cells were surface-stained with anti-human CD20-PerCP (2H7, BioLegend) and intracellularly stained using Cytofix/Cytoperm kit with anti-SIV<sub>mac251</sub> Nef mAb manually conjugated to Alexa 488 and Alexa 647-conjugated anti-human phospho-Akt (Ser473) (D9E, CST). For <xref ref-type="fig" rid="fig6">Figure 6B and C</xref>, cells acquired by FACS Canto II were analyzed using FACS Diva and FlowJo. Approximately 5 × 10<sup>4</sup> CD20<sup>+</sup> primary B cells and 3 × 10<sup>4</sup> CD19<sup>+</sup> Ramos B cells were analyzed.</p></sec><sec id="s4-20"><title>Peripheral SIV Env-specific B-cell responses</title><p>Peripheral SIV Env gp140-specific memory B cells (B<sub>mem</sub>) and PBs were measured by flow cytometry with procedures modified from previous reports and our experience (<xref ref-type="bibr" rid="bib103">Silveira et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Hau et al., 2022</xref>). First, cryopreserved/thawed PBMCs seeded in V-bottomed 96-well plates (Nunc) were blocked with 25 μg/ml of anti-human CD4 (clone L200: BD) in 100 μl volume for 15 minutes at 4°C. This concentration attains blockade of promiscuous SIV Env binding to CD4 comparable to levels by magnetic depletion of CD3<sup>+</sup> T cells (data not shown). After three washes, they were next stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. They were subsequently stained with the following anti-human antibodies and fluorochromes for 30 minutes at 4°C with combinations as follows; PB/B<sub>mem</sub>: anti-CD3-APC-Cy7 (SP34-2, BD Pharmingen), anti-CD8-APC-Cy7 (RPA-T8, BD Pharmingen), anti-CD14-APC-Cy7 (M5E2, BioLegend), anti-CD16-APC-Cy7 (3G8, BioLegend), streptavidin-Brilliant Violet 421 (BioLegend), anti-CD19-PC5.5 (J3-119, Beckman Coulter) and Live/Dead Aqua (Invitrogen); PB: anti-CD10-APC-Cy7 (HI10a, BioLegend), anti-CD11c-PE-Cy7 (3.9, BioLegend), anti-CD123-PE-Cy7 (6H6, BioLegend), and anti-HLA-DR-PE-Texas Red (TU36, Invitrogen); B<sub>mem</sub>: anti-CD27-PE/Dazzle 594 (M-T271, BioLegend), anti-CD10-PE-Cy7 (HI10a, BioLegend), anti-IgD-FITC (DaKo), anti-CD38-Alexa 647 (AT1, Santa Cruz Biotechnology), anti-IgG-Alexa 700 (G18-145, BD Pharmingen), and anti-CD138-PE (DL-101, eBioscience). After two washes, B<sub>mem</sub> samples were suspended in 0.8% PFA/PBS. For PB staining, surface-stained cells were further processed with Cytofix/Cytoperm kit (BD) for 20 minutes at 4°C, washed twice, and next intracellularly stained with 10 μg/ml of recombinant SIV<sub>mac239</sub> Env gp140-biotin (Immune Technology) for 30 minutes at 4°C. After three washes, they were next stained with anti-human IgG-PE (G18-145, BD), anti-human/mouse IRF4-eFluor 660 (3E4, eBioscience), anti-human Ki67-Alexa 700 (B56, BD Pharmingen), and streptavidin-Alexa 488 (BioLegend) for 30 minutes at 4°C. After final two washes, cells were suspended in 0.8% PFA/PBS. Cells acquired with FACS LSRII Fortessa were analyzed with FACS Diva and FlowJo. Approximately 1.5 × 10<sup>5</sup> PBMCs were acquired for B<sub>mem</sub> and 4 × 10<sup>5</sup> PBMCs were acquired for PB analyses (<xref ref-type="fig" rid="fig6">Figure 6</xref>). All centrifugations for washing (1200 × <italic>g</italic>, 2 minutes) were performed at 4°C. Env-specific PB frequencies were 0 cells/million PBMCs for pre-challenge samples in all animals examined, ruling out background confounding for high-sensitivity quantitation of the population.</p></sec><sec id="s4-21"><title>Statistical analysis</title><p>Analyses were performed using Prism 8 (GraphPad Software). p&lt;0.05 was considered significant in two-tailed unpaired <italic>t</italic>-tests, paired <italic>t</italic>-tests, Mann–Whitney <italic>U</italic> tests, Fisher’s exact tests, Wilcoxon signed-rank tests, one-way ANOVA with Tukey’s post hoc multiple comparison tests and two-way ANOVA with Sidak’s post hoc multiple comparison tests. For analysis of Nef-invaded B-cell pAkt levels, median fluorescence intensities (mFIs) were analyzed due to relatively small numbers of Nef<sup>+</sup> B cells. Analyses involving pAkt Ser473 levels all derived comparable results between mFI and MFI for WT versus Nef-G63E virus. Machine learning-based rating of Nef signal parameters was verified with IDEAS 6.3 Machine Learning Module (Luminex).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88849-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data were analyzed using existing computational packages. The accession number for the transcriptome data [WT SIVmac239-infected HSC-F cell line (n = 3), Nef-G63E SIVmac239-infected HSC-F cell line (n = 3) and uninfected HSC-F cell line (n = 3)] has been deposited under the accession number GenBank: GSE65806.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Gene expression profile in CD4+ T-cell infection with a SIV mutant related to altered humoral immune responses</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65806">GSE65806</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Fumiko Ono, Koji Hanari, Katsuhiko Komatsuzaki, Akio Hiyaoka, Hiromi Ogawa, Keiko Oto, Hirofumi Akari, Yasuhiro Yasutomi, Hiromi Sakawaki, Tomoyuki Miura, and Yoshio Koyanagi for animal experiment assistance; Hiroyuki Kogure, Sayuri Seki, and Julia R Hirsiger for imaging cytometry technical assistance; and Masako Nishizawa, Trang Thi Thu Hau, Shigeyoshi Harada, Takushi Nomura, Akiko Takeda, Taku Nakane, Nami Iwamoto, Taeko K Naruse, Akinori Kimura, and Mark S de Souza for their help. HY thanks Shoi Shi, Bettina Stolp, Jens V Stein, Makoto Yamagishi, and Yusuke Yanagi for conceptual discussions, and Jun Abe and Mike Recher for collaborative support.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnan</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>RK</given-names></name><name><surname>Gillis</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>FE</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Camp</surname><given-names>JV</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Connole</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Piatak</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Kozlowski</surname><given-names>PA</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name><name><surname>Haase</surname><given-names>AT</given-names></name><name><surname>Johnson</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persistent low-level replication of SIVΔnef drives maturation of antibody and CD8 T cell responses to induce protective immunity against vaginal SIV infection</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1006104</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006104</pub-id><pub-id pub-id-type="pmid">27959961</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akari</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Terao</surname><given-names>K</given-names></name><name><surname>Otani</surname><given-names>I</given-names></name><name><surname>Fukasawa</surname><given-names>M</given-names></name><name><surname>Mukai</surname><given-names>R</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>In vitro immortalization of old world monkey T lymphocytes with herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses</article-title><source>Virology</source><volume>218</volume><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1006/viro.1996.0207</pub-id><pub-id pub-id-type="pmid">8610465</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Qureshah</surname><given-names>F</given-names></name><name><surname>Sagadiev</surname><given-names>S</given-names></name><name><surname>Thouvenel</surname><given-names>CD</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Hua</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Acharya</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RG</given-names></name><name><surname>Rawlings</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Activated PI3Kδ signals compromise plasma cell survival via limiting autophagy and increasing ER stress</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20211035</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211035</pub-id><pub-id pub-id-type="pmid">34586341</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angulo</surname><given-names>I</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Garçon</surname><given-names>F</given-names></name><name><surname>Banham-Hall</surname><given-names>E</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Leahy</surname><given-names>TR</given-names></name><name><surname>Baxendale</surname><given-names>H</given-names></name><name><surname>Coulter</surname><given-names>T</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Blake-Palmer</surname><given-names>K</given-names></name><name><surname>Perisic</surname><given-names>O</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Maes</surname><given-names>M</given-names></name><name><surname>Fiddler</surname><given-names>C</given-names></name><name><surname>Juss</surname><given-names>J</given-names></name><name><surname>Cilliers</surname><given-names>D</given-names></name><name><surname>Markelj</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Farmer</surname><given-names>G</given-names></name><name><surname>Kielkowska</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Kracker</surname><given-names>S</given-names></name><name><surname>Debré</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Pellier</surname><given-names>I</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Barcenas-Morales</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>L</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Abinun</surname><given-names>M</given-names></name><name><surname>Clatworthy</surname><given-names>M</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Chilvers</surname><given-names>ER</given-names></name><name><surname>Cant</surname><given-names>AJ</given-names></name><name><surname>Kumararatne</surname><given-names>D</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Condliffe</surname><given-names>A</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage</article-title><source>Science</source><volume>342</volume><fpage>866</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1126/science.1243292</pub-id><pub-id pub-id-type="pmid">24136356</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Tsumura</surname><given-names>M</given-names></name><name><surname>Yeh</surname><given-names>T-W</given-names></name><name><surname>Mitsui-Sekinaka</surname><given-names>K</given-names></name><name><surname>Tsujita</surname><given-names>Y</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Ohara</surname><given-names>O</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Nonoyama</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>568</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00568</pub-id><pub-id pub-id-type="pmid">29675019</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Kane</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Lenthall</surname><given-names>H</given-names></name><name><surname>Payne</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Brigden</surname><given-names>H</given-names></name><name><surname>French</surname><given-names>E</given-names></name><name><surname>Bier</surname><given-names>J</given-names></name><name><surname>Hermes</surname><given-names>JR</given-names></name><name><surname>Zahra</surname><given-names>D</given-names></name><name><surname>Sewell</surname><given-names>WA</given-names></name><name><surname>Butt</surname><given-names>D</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Boztug</surname><given-names>K</given-names></name><name><surname>Meyts</surname><given-names>I</given-names></name><name><surname>Choo</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Berglund</surname><given-names>LJ</given-names></name><name><surname>Gray</surname><given-names>P</given-names></name><name><surname>O’Sullivan</surname><given-names>M</given-names></name><name><surname>Cole</surname><given-names>T</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Ma</surname><given-names>CS</given-names></name><name><surname>Burkhart</surname><given-names>C</given-names></name><name><surname>Corcoran</surname><given-names>LM</given-names></name><name><surname>Phan</surname><given-names>TG</given-names></name><name><surname>Brink</surname><given-names>R</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Germline-activating mutations in <italic>PIK3CD</italic> compromise B cell development and function</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2073</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1084/jem.20180010</pub-id><pub-id pub-id-type="pmid">30018075</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avin</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Porat</surname><given-names>Z</given-names></name><name><surname>Abramson</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantitative analysis of protein-protein interactions and post-translational modifications in rare immune populations</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1524</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01808-6</pub-id><pub-id pub-id-type="pmid">29142256</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battegay</surname><given-names>M</given-names></name><name><surname>Moskophidis</surname><given-names>D</given-names></name><name><surname>Waldner</surname><given-names>H</given-names></name><name><surname>Bründler</surname><given-names>MA</given-names></name><name><surname>Fung-Leung</surname><given-names>WP</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Hengartner</surname><given-names>H</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells</article-title><source>Journal of Immunology</source><volume>151</volume><fpage>5408</fpage><lpage>5415</lpage><pub-id pub-id-type="pmid">7693811</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumjohann</surname><given-names>D</given-names></name><name><surname>Preite</surname><given-names>S</given-names></name><name><surname>Reboldi</surname><given-names>A</given-names></name><name><surname>Ronchi</surname><given-names>F</given-names></name><name><surname>Ansel</surname><given-names>KM</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype</article-title><source>Immunity</source><volume>38</volume><fpage>596</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.020</pub-id><pub-id pub-id-type="pmid">23499493</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>T</given-names></name><name><surname>Peppa</surname><given-names>D</given-names></name><name><surname>Pedroza-Pacheco</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Cain</surname><given-names>DW</given-names></name><name><surname>Henao</surname><given-names>R</given-names></name><name><surname>Venkat</surname><given-names>V</given-names></name><name><surname>Hora</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Vandergrift</surname><given-names>NA</given-names></name><name><surname>Overman</surname><given-names>RG</given-names></name><name><surname>Edwards</surname><given-names>RW</given-names></name><name><surname>Woods</surname><given-names>CW</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Ginsburg</surname><given-names>GS</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses</article-title><source>Cell</source><volume>175</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.08.064</pub-id><pub-id pub-id-type="pmid">30270043</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>DP</given-names></name><name><surname>Collignon</surname><given-names>C</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys</article-title><source>Journal of Virology</source><volume>67</volume><fpage>4104</fpage><lpage>4113</lpage><pub-id pub-id-type="doi">10.1128/JVI.67.7.4104-4113.1993</pub-id><pub-id pub-id-type="pmid">8510218</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>EM</given-names></name><name><surname>Nunez</surname><given-names>R</given-names></name><name><surname>Hope</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity</article-title><source>Journal of Virology</source><volume>78</volume><fpage>5745</fpage><lpage>5755</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.11.5745-5755.2004</pub-id><pub-id pub-id-type="pmid">15140972</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>TI</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Bacon</surname><given-names>CM</given-names></name><name><surname>Babar</surname><given-names>J</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Screaton</surname><given-names>N</given-names></name><name><surname>Goodlad</surname><given-names>JR</given-names></name><name><surname>Farmer</surname><given-names>G</given-names></name><name><surname>Steele</surname><given-names>CL</given-names></name><name><surname>Leahy</surname><given-names>TR</given-names></name><name><surname>Doffinger</surname><given-names>R</given-names></name><name><surname>Baxendale</surname><given-names>H</given-names></name><name><surname>Bernatoniene</surname><given-names>J</given-names></name><name><surname>Edgar</surname><given-names>JDM</given-names></name><name><surname>Longhurst</surname><given-names>HJ</given-names></name><name><surname>Ehl</surname><given-names>S</given-names></name><name><surname>Speckmann</surname><given-names>C</given-names></name><name><surname>Grimbacher</surname><given-names>B</given-names></name><name><surname>Sediva</surname><given-names>A</given-names></name><name><surname>Milota</surname><given-names>T</given-names></name><name><surname>Faust</surname><given-names>SN</given-names></name><name><surname>Williams</surname><given-names>AP</given-names></name><name><surname>Hayman</surname><given-names>G</given-names></name><name><surname>Kucuk</surname><given-names>ZY</given-names></name><name><surname>Hague</surname><given-names>R</given-names></name><name><surname>French</surname><given-names>P</given-names></name><name><surname>Brooker</surname><given-names>R</given-names></name><name><surname>Forsyth</surname><given-names>P</given-names></name><name><surname>Herriot</surname><given-names>R</given-names></name><name><surname>Cancrini</surname><given-names>C</given-names></name><name><surname>Palma</surname><given-names>P</given-names></name><name><surname>Ariganello</surname><given-names>P</given-names></name><name><surname>Conlon</surname><given-names>N</given-names></name><name><surname>Feighery</surname><given-names>C</given-names></name><name><surname>Gavin</surname><given-names>PJ</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Ibrahim</surname><given-names>MAA</given-names></name><name><surname>Markelj</surname><given-names>G</given-names></name><name><surname>Abinun</surname><given-names>M</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Pellier</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Touzot</surname><given-names>F</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name><name><surname>Burns</surname><given-names>SO</given-names></name><name><surname>Savic</surname><given-names>S</given-names></name><name><surname>Kumararatne</surname><given-names>DS</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Kracker</surname><given-names>S</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Okkenhaug</surname><given-names>K</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Nejentsev</surname><given-names>S</given-names></name><name><surname>Condliffe</surname><given-names>AM</given-names></name><name><surname>Cant</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>139</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.06.021</pub-id><pub-id pub-id-type="pmid">27555459</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubas</surname><given-names>RA</given-names></name><name><surname>Mudd</surname><given-names>JC</given-names></name><name><surname>Savoye</surname><given-names>A-L</given-names></name><name><surname>Perreau</surname><given-names>M</given-names></name><name><surname>van Grevenynghe</surname><given-names>J</given-names></name><name><surname>Metcalf</surname><given-names>T</given-names></name><name><surname>Connick</surname><given-names>E</given-names></name><name><surname>Meditz</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Abesada-Terk</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Jacobson</surname><given-names>JM</given-names></name><name><surname>Brooks</surname><given-names>AD</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Pantaleo</surname><given-names>G</given-names></name><name><surname>Lederman</surname><given-names>MM</given-names></name><name><surname>Haddad</surname><given-names>EK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inadequate T follicular cell help impairs B cell immunity during HIV infection</article-title><source>Nature Medicine</source><volume>19</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/nm.3109</pub-id><pub-id pub-id-type="pmid">23475201</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumont</surname><given-names>M-C</given-names></name><name><surname>Diop</surname><given-names>O</given-names></name><name><surname>Vaslin</surname><given-names>B</given-names></name><name><surname>Elbim</surname><given-names>C</given-names></name><name><surname>Viollet</surname><given-names>L</given-names></name><name><surname>Monceaux</surname><given-names>V</given-names></name><name><surname>Lay</surname><given-names>S</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Le Grand</surname><given-names>R</given-names></name><name><surname>Müller-Trutwin</surname><given-names>M</given-names></name><name><surname>Hurtrel</surname><given-names>B</given-names></name><name><surname>Estaquier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Early divergence in lymphoid tissue apoptosis between pathogenic and nonpathogenic simian immunodeficiency virus infections of nonhuman primates</article-title><source>Journal of Virology</source><volume>82</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1128/JVI.00450-07</pub-id><pub-id pub-id-type="pmid">18032487</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dornan</surname><given-names>GL</given-names></name><name><surname>Siempelkamp</surname><given-names>BD</given-names></name><name><surname>Jenkins</surname><given-names>ML</given-names></name><name><surname>Vadas</surname><given-names>O</given-names></name><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Burke</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1</article-title><source>PNAS</source><volume>114</volume><fpage>1982</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617244114</pub-id><pub-id pub-id-type="pmid">28167755</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Ambrozak</surname><given-names>DR</given-names></name><name><surname>Hill</surname><given-names>BJ</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Casazza</surname><given-names>JP</given-names></name><name><surname>Kuruppu</surname><given-names>J</given-names></name><name><surname>Kunstman</surname><given-names>K</given-names></name><name><surname>Wolinsky</surname><given-names>S</given-names></name><name><surname>Grossman</surname><given-names>Z</given-names></name><name><surname>Dybul</surname><given-names>M</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>DA</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>HIV preferentially infects hiv-specific CD4+ T cells</article-title><source>Nature</source><volume>417</volume><fpage>95</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/417095a</pub-id><pub-id pub-id-type="pmid">11986671</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DT</given-names></name><name><surname>O’Connor</surname><given-names>DH</given-names></name><name><surname>Jing</surname><given-names>P</given-names></name><name><surname>Dzuris</surname><given-names>JL</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>da Silva</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Horton</surname><given-names>H</given-names></name><name><surname>Venham</surname><given-names>JE</given-names></name><name><surname>Rudersdorf</surname><given-names>RA</given-names></name><name><surname>Vogel</surname><given-names>T</given-names></name><name><surname>Pauza</surname><given-names>CD</given-names></name><name><surname>Bontrop</surname><given-names>RE</given-names></name><name><surname>DeMars</surname><given-names>R</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>AL</given-names></name><name><surname>Watkins</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef</article-title><source>Nature Medicine</source><volume>5</volume><fpage>1270</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1038/15224</pub-id><pub-id pub-id-type="pmid">10545993</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallet</surname><given-names>B</given-names></name><name><surname>Narr</surname><given-names>K</given-names></name><name><surname>Ertuna</surname><given-names>YI</given-names></name><name><surname>Remy</surname><given-names>M</given-names></name><name><surname>Sommerstein</surname><given-names>R</given-names></name><name><surname>Cornille</surname><given-names>K</given-names></name><name><surname>Kreutzfeldt</surname><given-names>M</given-names></name><name><surname>Page</surname><given-names>N</given-names></name><name><surname>Zimmer</surname><given-names>G</given-names></name><name><surname>Geier</surname><given-names>F</given-names></name><name><surname>Straub</surname><given-names>T</given-names></name><name><surname>Pircher</surname><given-names>H</given-names></name><name><surname>Larimore</surname><given-names>K</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Pinschewer</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interferon-driven deletion of antiviral B cells at the onset of chronic infection</article-title><source>Science Immunology</source><volume>1</volume><elocation-id>eaah6817</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aah6817</pub-id><pub-id pub-id-type="pmid">27872905</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>François</surname><given-names>F</given-names></name><name><surname>Klotman</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages</article-title><source>Journal of Virology</source><volume>77</volume><fpage>2539</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.4.2539-2549.2003</pub-id><pub-id pub-id-type="pmid">12551992</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruman</surname><given-names>DA</given-names></name><name><surname>Snapper</surname><given-names>SB</given-names></name><name><surname>Yballe</surname><given-names>CM</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>JY</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha</article-title><source>Science</source><volume>283</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1126/science.283.5400.393</pub-id><pub-id pub-id-type="pmid">9888855</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukazawa</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Cameron</surname><given-names>MJ</given-names></name><name><surname>Lefebvre</surname><given-names>F</given-names></name><name><surname>Lum</surname><given-names>R</given-names></name><name><surname>Coombes</surname><given-names>N</given-names></name><name><surname>Mahyari</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>SI</given-names></name><name><surname>Bae</surname><given-names>JY</given-names></name><name><surname>Iii</surname><given-names>MDR</given-names></name><name><surname>Swanson</surname><given-names>T</given-names></name><name><surname>Legasse</surname><given-names>AW</given-names></name><name><surname>Sylwester</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>SG</given-names></name><name><surname>Smith</surname><given-names>AT</given-names></name><name><surname>Stafova</surname><given-names>P</given-names></name><name><surname>Shoemaker</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Oswald</surname><given-names>K</given-names></name><name><surname>Axthelm</surname><given-names>MK</given-names></name><name><surname>McDermott</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>G</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Edlefsen</surname><given-names>PT</given-names></name><name><surname>Piatak</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Sékaly</surname><given-names>RP</given-names></name><name><surname>Picker</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1673</fpage><lpage>1681</lpage><pub-id pub-id-type="doi">10.1038/nm.2934</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauduin</surname><given-names>MC</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Barabasz</surname><given-names>A</given-names></name><name><surname>Carville</surname><given-names>A</given-names></name><name><surname>Piatak</surname><given-names>M</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name><name><surname>Johnson</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>2661</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1084/jem.20060134</pub-id><pub-id pub-id-type="pmid">17116733</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname><given-names>M</given-names></name><name><surname>Fackler</surname><given-names>OT</given-names></name><name><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structure--function relationships in HIV-1 nef</article-title><source>EMBO Reports</source><volume>2</volume><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1093/embo-reports/kve141</pub-id><pub-id pub-id-type="pmid">11463741</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitlin</surname><given-names>AD</given-names></name><name><surname>Shulman</surname><given-names>Z</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal selection in the germinal centre by regulated proliferation and hypermutation</article-title><source>Nature</source><volume>509</volume><fpage>637</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/nature13300</pub-id><pub-id pub-id-type="pmid">24805232</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>ES</given-names></name><name><surname>Madiga</surname><given-names>MC</given-names></name><name><surname>Hermanus</surname><given-names>T</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Wibmer</surname><given-names>CK</given-names></name><name><surname>Tumba</surname><given-names>NL</given-names></name><name><surname>Werner</surname><given-names>L</given-names></name><name><surname>Mlisana</surname><given-names>K</given-names></name><name><surname>Sibeko</surname><given-names>S</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Abdool Karim</surname><given-names>SS</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><collab>and the CAPRISA002 Study Team</collab></person-group><year iso-8601-date="2011">2011</year><article-title>The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 <sup>+</sup> T cell decline and high viral load during acute infection</article-title><source>Journal of Virology</source><volume>85</volume><fpage>4828</fpage><lpage>4840</lpage><pub-id pub-id-type="doi">10.1128/JVI.00198-11</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haigwood</surname><given-names>NL</given-names></name><name><surname>Watson</surname><given-names>A</given-names></name><name><surname>Sutton</surname><given-names>WF</given-names></name><name><surname>McClure</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>A</given-names></name><name><surname>Ranchalis</surname><given-names>J</given-names></name><name><surname>Travis</surname><given-names>B</given-names></name><name><surname>Voss</surname><given-names>G</given-names></name><name><surname>Letvin</surname><given-names>NL</given-names></name><name><surname>Hu</surname><given-names>SL</given-names></name><name><surname>Hirsch</surname><given-names>VM</given-names></name><name><surname>Johnson</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile</article-title><source>Immunology Letters</source><volume>51</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0165-2478(96)02563-1</pub-id><pub-id pub-id-type="pmid">8811353</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haralick</surname><given-names>RM</given-names></name><name><surname>Shanmugam</surname><given-names>K</given-names></name><name><surname>Dinstein</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>Textural features for image classification</article-title><source>IEEE Transactions on Systems, Man, and Cybernetics</source><volume>SMC-3</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1109/TSMC.1973.4309314</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Bishop</surname><given-names>KN</given-names></name><name><surname>Sheehy</surname><given-names>AM</given-names></name><name><surname>Craig</surname><given-names>HM</given-names></name><name><surname>Petersen-Mahrt</surname><given-names>SK</given-names></name><name><surname>Watt</surname><given-names>IN</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>DNA deamination mediates innate immunity to retroviral infection</article-title><source>Cell</source><volume>113</volume><fpage>803</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00423-9</pub-id><pub-id pub-id-type="pmid">12809610</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Bhuyan</surname><given-names>F</given-names></name><name><surname>Hiyoshi</surname><given-names>M</given-names></name><name><surname>Noyori</surname><given-names>O</given-names></name><name><surname>Nasser</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kondoh</surname><given-names>Y</given-names></name><name><surname>Osada</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>S</given-names></name><name><surname>Hase</surname><given-names>K</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Suzu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Potential role of the formation of tunneling nanotubes in HIV-1 spread in macrophages</article-title><source>Journal of Immunology</source><volume>196</volume><fpage>1832</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500845</pub-id><pub-id pub-id-type="pmid">26773158</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hau</surname><given-names>TTT</given-names></name><name><surname>Nishizawa</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name><name><surname>Phan</surname><given-names>MH</given-names></name><name><surname>Kanno</surname><given-names>Y</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Matsuoka</surname><given-names>S</given-names></name><name><surname>Kawana-Tachikawa</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>WW</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>LAT</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection</article-title><source>AIDS</source><volume>36</volume><fpage>1629</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003323</pub-id><pub-id pub-id-type="pmid">35848590</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Carnathan</surname><given-names>DG</given-names></name><name><surname>Torrents de la Peña</surname><given-names>A</given-names></name><name><surname>Pauthner</surname><given-names>M</given-names></name><name><surname>Briney</surname><given-names>B</given-names></name><name><surname>Reiss</surname><given-names>SM</given-names></name><name><surname>Wood</surname><given-names>JS</given-names></name><name><surname>Kaushik</surname><given-names>K</given-names></name><name><surname>van Gils</surname><given-names>MJ</given-names></name><name><surname>Rosales</surname><given-names>SL</given-names></name><name><surname>van der Woude</surname><given-names>P</given-names></name><name><surname>Locci</surname><given-names>M</given-names></name><name><surname>Le</surname><given-names>KM</given-names></name><name><surname>de Taeye</surname><given-names>SW</given-names></name><name><surname>Sok</surname><given-names>D</given-names></name><name><surname>Mohammed</surname><given-names>AUR</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Gumber</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Kasturi</surname><given-names>SP</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Seumois</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV Env trimer</article-title><source>Cell Reports</source><volume>17</volume><fpage>2195</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.085</pub-id><pub-id pub-id-type="pmid">27880897</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>VM</given-names></name><name><surname>Santra</surname><given-names>S</given-names></name><name><surname>Goldstein</surname><given-names>S</given-names></name><name><surname>Plishka</surname><given-names>R</given-names></name><name><surname>Buckler-White</surname><given-names>A</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Ourmanov</surname><given-names>I</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><name><surname>Engle</surname><given-names>R</given-names></name><name><surname>Montefiori</surname><given-names>D</given-names></name><name><surname>Glowczwskie</surname><given-names>J</given-names></name><name><surname>Kunstman</surname><given-names>K</given-names></name><name><surname>Wolinsky</surname><given-names>S</given-names></name><name><surname>Letvin</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques</article-title><source>Journal of Virology</source><volume>78</volume><fpage>275</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.1.275-284.2004</pub-id><pub-id pub-id-type="pmid">14671109</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoof</surname><given-names>I</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>LE</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Lund</surname><given-names>O</given-names></name><name><surname>Buus</surname><given-names>S</given-names></name><name><surname>Nielsen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>NetMHCpan, a method for MHC class I binding prediction beyond humans</article-title><source>Immunogenetics</source><volume>61</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s00251-008-0341-z</pub-id><pub-id pub-id-type="pmid">19002680</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunziker</surname><given-names>L</given-names></name><name><surname>Recher</surname><given-names>M</given-names></name><name><surname>Macpherson</surname><given-names>AJ</given-names></name><name><surname>Ciurea</surname><given-names>A</given-names></name><name><surname>Freigang</surname><given-names>S</given-names></name><name><surname>Hengartner</surname><given-names>H</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections</article-title><source>Nature Immunology</source><volume>4</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1038/ni911</pub-id><pub-id pub-id-type="pmid">12627229</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iseda</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Poplimont</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>S</given-names></name><name><surname>Nakane</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Furukawa</surname><given-names>S</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Biphasic CD8+ T-cell defense in simian immunodeficiency virus control by acute-phase passive neutralizing antibody immunization</article-title><source>Journal of Virology</source><volume>90</volume><fpage>6276</fpage><lpage>6290</lpage><pub-id pub-id-type="doi">10.1128/JVI.00557-16</pub-id><pub-id pub-id-type="pmid">27122584</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Kawada</surname><given-names>M</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Matsuoka</surname><given-names>S</given-names></name><name><surname>Shiino</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Takiguchi</surname><given-names>M</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques</article-title><source>Journal of Virology</source><volume>86</volume><fpage>738</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1128/JVI.06226-11</pub-id><pub-id pub-id-type="pmid">22072784</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Seki</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells</article-title><source>Journal of Virology</source><volume>88</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/JVI.02634-13</pub-id><pub-id pub-id-type="pmid">24155398</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jauch</surname><given-names>AJ</given-names></name><name><surname>Bignucolo</surname><given-names>O</given-names></name><name><surname>Seki</surname><given-names>S</given-names></name><name><surname>Ghraichy</surname><given-names>M</given-names></name><name><surname>Delmonte</surname><given-names>OM</given-names></name><name><surname>von Niederhäusern</surname><given-names>V</given-names></name><name><surname>Higgins</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Nishizawa</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Baldrich</surname><given-names>A</given-names></name><name><surname>Köppen</surname><given-names>J</given-names></name><name><surname>Hirsiger</surname><given-names>JR</given-names></name><name><surname>Hupfer</surname><given-names>R</given-names></name><name><surname>Ehl</surname><given-names>S</given-names></name><name><surname>Rensing-Ehl</surname><given-names>A</given-names></name><name><surname>Hopfer</surname><given-names>H</given-names></name><name><surname>Prince</surname><given-names>SS</given-names></name><name><surname>Daley</surname><given-names>SR</given-names></name><name><surname>Marquardsen</surname><given-names>FA</given-names></name><name><surname>Meyer</surname><given-names>BJ</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Daikeler</surname><given-names>TD</given-names></name><name><surname>Diesch</surname><given-names>T</given-names></name><name><surname>Kühne</surname><given-names>T</given-names></name><name><surname>Helbling</surname><given-names>A</given-names></name><name><surname>Berkemeier</surname><given-names>C</given-names></name><name><surname>Heijnen</surname><given-names>I</given-names></name><name><surname>Navarini</surname><given-names>AA</given-names></name><name><surname>Trück</surname><given-names>J</given-names></name><name><surname>de Villartay</surname><given-names>J-P</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>CT</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Recher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>152</volume><fpage>500</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2023.03.022</pub-id><pub-id pub-id-type="pmid">37004747</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>B</given-names></name><name><surname>Serra-Moreno</surname><given-names>R</given-names></name><name><surname>Neidermyer</surname><given-names>W</given-names></name><name><surname>Rahmberg</surname><given-names>A</given-names></name><name><surname>Mackey</surname><given-names>J</given-names></name><name><surname>Fofana</surname><given-names>IB</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Westmoreland</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2</article-title><source>PLOS Pathogens</source><volume>5</volume><elocation-id>e1000429</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000429</pub-id><pub-id pub-id-type="pmid">19436700</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joas</surname><given-names>S</given-names></name><name><surname>Parrish</surname><given-names>EH</given-names></name><name><surname>Gnanadurai</surname><given-names>CW</given-names></name><name><surname>Lump</surname><given-names>E</given-names></name><name><surname>Stürzel</surname><given-names>CM</given-names></name><name><surname>Parrish</surname><given-names>NF</given-names></name><name><surname>Learn</surname><given-names>GH</given-names></name><name><surname>Sauermann</surname><given-names>U</given-names></name><name><surname>Neumann</surname><given-names>B</given-names></name><name><surname>Rensing</surname><given-names>KM</given-names></name><name><surname>Fuchs</surname><given-names>D</given-names></name><name><surname>Billingsley</surname><given-names>JM</given-names></name><name><surname>Bosinger</surname><given-names>SE</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Apetrei</surname><given-names>C</given-names></name><name><surname>Huot</surname><given-names>N</given-names></name><name><surname>Garcia-Tellez</surname><given-names>T</given-names></name><name><surname>Müller-Trutwin</surname><given-names>M</given-names></name><name><surname>Hotter</surname><given-names>D</given-names></name><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Stahl-Hennig</surname><given-names>C</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Species-specific host factors rather than virus-intrinsic virulence determine primate lentiviral pathogenicity</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>1371</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-03762-3</pub-id><pub-id pub-id-type="pmid">29636452</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joas</surname><given-names>S</given-names></name><name><surname>Sauermann</surname><given-names>U</given-names></name><name><surname>Roshani</surname><given-names>B</given-names></name><name><surname>Klippert</surname><given-names>A</given-names></name><name><surname>Daskalaki</surname><given-names>M</given-names></name><name><surname>Mätz-Rensing</surname><given-names>K</given-names></name><name><surname>Stolte-Leeb</surname><given-names>N</given-names></name><name><surname>Heigele</surname><given-names>A</given-names></name><name><surname>Tharp</surname><given-names>GK</given-names></name><name><surname>Gupta</surname><given-names>PM</given-names></name><name><surname>Nelson</surname><given-names>S</given-names></name><name><surname>Bosinger</surname><given-names>S</given-names></name><name><surname>Parodi</surname><given-names>L</given-names></name><name><surname>Giavedoni</surname><given-names>L</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Stahl-Hennig</surname><given-names>C</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nef-mediated CD3-TCR downmodulation dampens acute inflammation and promotes SIV immune evasion</article-title><source>Cell Reports</source><volume>30</volume><fpage>2261</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.01.069</pub-id><pub-id pub-id-type="pmid">32075764</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RP</given-names></name><name><surname>Glickman</surname><given-names>RL</given-names></name><name><surname>Yang</surname><given-names>JQ</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Dion</surname><given-names>JT</given-names></name><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus</article-title><source>Journal of Virology</source><volume>71</volume><fpage>7711</fpage><lpage>7718</lpage><pub-id pub-id-type="doi">10.1128/JVI.71.10.7711-7718.1997</pub-id><pub-id pub-id-type="pmid">9311855</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>C</given-names></name><name><surname>Kashefi</surname><given-names>K</given-names></name><name><surname>Hollinshead</surname><given-names>M</given-names></name><name><surname>Sattentau</surname><given-names>QJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse</article-title><source>The Journal of Experimental Medicine</source><volume>199</volume><fpage>283</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1084/jem.20030648</pub-id><pub-id pub-id-type="pmid">14734528</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junt</surname><given-names>T</given-names></name><name><surname>Moseman</surname><given-names>EA</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name><name><surname>Massberg</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>PA</given-names></name><name><surname>Boes</surname><given-names>M</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Henrickson</surname><given-names>SE</given-names></name><name><surname>Shayakhmetov</surname><given-names>DM</given-names></name><name><surname>Di Paolo</surname><given-names>NC</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Whelan</surname><given-names>SP</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells</article-title><source>Nature</source><volume>450</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/nature06287</pub-id><pub-id pub-id-type="pmid">17934446</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawada</surname><given-names>M</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Igarashi</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>DI</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine</article-title><source>Journal of Virology</source><volume>81</volume><fpage>5202</fpage><lpage>5211</lpage><pub-id pub-id-type="doi">10.1128/JVI.02881-06</pub-id><pub-id pub-id-type="pmid">17344296</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>SG</given-names></name><name><surname>Wagner</surname><given-names>AJ</given-names></name><name><surname>Conzen</surname><given-names>SD</given-names></name><name><surname>Jordán</surname><given-names>J</given-names></name><name><surname>Bellacosa</surname><given-names>A</given-names></name><name><surname>Tsichlis</surname><given-names>PN</given-names></name><name><surname>Hay</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal</article-title><source>Genes &amp; Development</source><volume>11</volume><fpage>701</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1101/gad.11.6.701</pub-id><pub-id pub-id-type="pmid">9087425</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kestler</surname><given-names>HW</given-names><suffix>III</suffix></name><name><surname>Ringler</surname><given-names>DJ</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Panicali</surname><given-names>DL</given-names></name><name><surname>Sehgal</surname><given-names>PK</given-names></name><name><surname>Daniel</surname><given-names>MD</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Importance of the nef gene for maintenance of high virus loads and for development of AIDS</article-title><source>Cell</source><volume>65</volume><fpage>651</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(91)90097-I</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>H</given-names></name><name><surname>Sumner</surname><given-names>RP</given-names></name><name><surname>Rasaiyaah</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>CP</given-names></name><name><surname>Rodriguez-Plata</surname><given-names>MT</given-names></name><name><surname>Van Tulleken</surname><given-names>C</given-names></name><name><surname>Fink</surname><given-names>D</given-names></name><name><surname>Zuliani-Alvarez</surname><given-names>L</given-names></name><name><surname>Thorne</surname><given-names>L</given-names></name><name><surname>Stirling</surname><given-names>D</given-names></name><name><surname>Milne</surname><given-names>RS</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport</article-title><source>eLife</source><volume>9</volume><elocation-id>e60821</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60821</pub-id><pub-id pub-id-type="pmid">33300875</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D-H</given-names></name><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Latek</surname><given-names>RR</given-names></name><name><surname>Guntur</surname><given-names>KVP</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Tempst</surname><given-names>P</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR</article-title><source>Molecular Cell</source><volume>11</volume><fpage>895</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00114-X</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Greenough</surname><given-names>TC</given-names></name><name><surname>Brettler</surname><given-names>DB</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection</article-title><source>The New England Journal of Medicine</source><volume>332</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1056/NEJM199501263320405</pub-id><pub-id pub-id-type="pmid">7808489</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Scandella</surname><given-names>E</given-names></name><name><surname>Danuser</surname><given-names>R</given-names></name><name><surname>Onder</surname><given-names>L</given-names></name><name><surname>Nitschké</surname><given-names>M</given-names></name><name><surname>Fukui</surname><given-names>Y</given-names></name><name><surname>Halin</surname><given-names>C</given-names></name><name><surname>Ludewig</surname><given-names>B</given-names></name><name><surname>Stein</surname><given-names>JV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathway</article-title><source>Blood</source><volume>115</volume><fpage>4725</fpage><lpage>4733</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-250118</pub-id><pub-id pub-id-type="pmid">20185585</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Abbas</surname><given-names>W</given-names></name><name><surname>Colin</surname><given-names>L</given-names></name><name><surname>Khan</surname><given-names>KA</given-names></name><name><surname>Bouchat</surname><given-names>S</given-names></name><name><surname>Varin</surname><given-names>A</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Gatot</surname><given-names>J-S</given-names></name><name><surname>Kabeya</surname><given-names>K</given-names></name><name><surname>Vanhulle</surname><given-names>C</given-names></name><name><surname>Delacourt</surname><given-names>N</given-names></name><name><surname>Pasquereau</surname><given-names>S</given-names></name><name><surname>Coquard</surname><given-names>L</given-names></name><name><surname>Borch</surname><given-names>A</given-names></name><name><surname>König</surname><given-names>R</given-names></name><name><surname>Clumeck</surname><given-names>N</given-names></name><name><surname>De Wit</surname><given-names>S</given-names></name><name><surname>Rohr</surname><given-names>O</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name><name><surname>Fulop</surname><given-names>T</given-names></name><name><surname>Van Lint</surname><given-names>C</given-names></name><name><surname>Herbein</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>e24090</elocation-id><pub-id pub-id-type="doi">10.1038/srep24090</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laguette</surname><given-names>N</given-names></name><name><surname>Sobhian</surname><given-names>B</given-names></name><name><surname>Casartelli</surname><given-names>N</given-names></name><name><surname>Ringeard</surname><given-names>M</given-names></name><name><surname>Chable-Bessia</surname><given-names>C</given-names></name><name><surname>Ségéral</surname><given-names>E</given-names></name><name><surname>Yatim</surname><given-names>A</given-names></name><name><surname>Emiliani</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Benkirane</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx</article-title><source>Nature</source><volume>474</volume><fpage>654</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/nature10117</pub-id><pub-id pub-id-type="pmid">21613998</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>S</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Hopfensperger</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Hotter</surname><given-names>D</given-names></name><name><surname>De Jesus</surname><given-names>PD</given-names></name><name><surname>Herbert</surname><given-names>KM</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>van der Merwe</surname><given-names>JA</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Sauter</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses</article-title><source>eLife</source><volume>8</volume><elocation-id>e41930</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.41930</pub-id><pub-id pub-id-type="pmid">30717826</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leuchowius</surname><given-names>KJ</given-names></name><name><surname>Weibrecht</surname><given-names>I</given-names></name><name><surname>Landegren</surname><given-names>U</given-names></name><name><surname>Gedda</surname><given-names>L</given-names></name><name><surname>Söderberg</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family</article-title><source>Cytometry. Part A</source><volume>75</volume><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.20771</pub-id><pub-id pub-id-type="pmid">19650109</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levesque</surname><given-names>MC</given-names></name><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Hwang</surname><given-names>K-K</given-names></name><name><surname>Marshall</surname><given-names>DJ</given-names></name><name><surname>Whitesides</surname><given-names>JF</given-names></name><name><surname>Amos</surname><given-names>JD</given-names></name><name><surname>Gurley</surname><given-names>TC</given-names></name><name><surname>Allgood</surname><given-names>S</given-names></name><name><surname>Haynes</surname><given-names>BB</given-names></name><name><surname>Vandergrift</surname><given-names>NA</given-names></name><name><surname>Plonk</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>DC</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Goepfert</surname><given-names>PA</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Schmitz</surname><given-names>JE</given-names></name><name><surname>Eron</surname><given-names>JJ</given-names></name><name><surname>Shaheen</surname><given-names>NJ</given-names></name><name><surname>Hicks</surname><given-names>CB</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Markowitz</surname><given-names>M</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection</article-title><source>PLOS Medicine</source><volume>6</volume><elocation-id>e1000107</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000107</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichterfeld</surname><given-names>M</given-names></name><name><surname>Kavanagh</surname><given-names>DG</given-names></name><name><surname>Williams</surname><given-names>KL</given-names></name><name><surname>Moza</surname><given-names>B</given-names></name><name><surname>Mui</surname><given-names>SK</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Sivamurthy</surname><given-names>R</given-names></name><name><surname>Allgaier</surname><given-names>R</given-names></name><name><surname>Pereyra</surname><given-names>F</given-names></name><name><surname>Trocha</surname><given-names>A</given-names></name><name><surname>Feeney</surname><given-names>M</given-names></name><name><surname>Gandhi</surname><given-names>RT</given-names></name><name><surname>Rosenberg</surname><given-names>ES</given-names></name><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Allen</surname><given-names>R</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Sundberg</surname><given-names>EJ</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>2813</fpage><lpage>2824</lpage><pub-id pub-id-type="doi">10.1084/jem.20061865</pub-id><pub-id pub-id-type="pmid">18025130</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limon</surname><given-names>JJ</given-names></name><name><surname>So</surname><given-names>L</given-names></name><name><surname>Jellbauer</surname><given-names>S</given-names></name><name><surname>Chiu</surname><given-names>H</given-names></name><name><surname>Corado</surname><given-names>J</given-names></name><name><surname>Sykes</surname><given-names>SM</given-names></name><name><surname>Raffatellu</surname><given-names>M</given-names></name><name><surname>Fruman</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition</article-title><source>PNAS</source><volume>111</volume><fpage>E5076</fpage><lpage>E5085</lpage><pub-id pub-id-type="doi">10.1073/pnas.1407104111</pub-id><pub-id pub-id-type="pmid">25385646</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindqvist</surname><given-names>M</given-names></name><name><surname>van Lunzen</surname><given-names>J</given-names></name><name><surname>Soghoian</surname><given-names>DZ</given-names></name><name><surname>Kuhl</surname><given-names>BD</given-names></name><name><surname>Ranasinghe</surname><given-names>S</given-names></name><name><surname>Kranias</surname><given-names>G</given-names></name><name><surname>Flanders</surname><given-names>MD</given-names></name><name><surname>Cutler</surname><given-names>S</given-names></name><name><surname>Yudanin</surname><given-names>N</given-names></name><name><surname>Muller</surname><given-names>MI</given-names></name><name><surname>Davis</surname><given-names>I</given-names></name><name><surname>Farber</surname><given-names>D</given-names></name><name><surname>Hartjen</surname><given-names>P</given-names></name><name><surname>Haag</surname><given-names>F</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Schulze zur Wiesch</surname><given-names>J</given-names></name><name><surname>Streeck</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expansion of HIV-specific T follicular helper cells in chronic HIV infection</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>3271</fpage><lpage>3280</lpage><pub-id pub-id-type="doi">10.1172/JCI64314</pub-id><pub-id pub-id-type="pmid">22922259</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locci</surname><given-names>M</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C</given-names></name><name><surname>Landais</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Kroenke</surname><given-names>MA</given-names></name><name><surname>Arlehamn</surname><given-names>CL</given-names></name><name><surname>Su</surname><given-names>LF</given-names></name><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Haddad</surname><given-names>EK</given-names></name><collab>International AIDS Vaccine Initiative Protocol C Principal Investigators</collab><name><surname>Poignard</surname><given-names>P</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses</article-title><source>Immunity</source><volume>39</volume><fpage>758</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.031</pub-id><pub-id pub-id-type="pmid">24035365</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>CL</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Niemela</surname><given-names>JE</given-names></name><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Avery</surname><given-names>DT</given-names></name><name><surname>Moens</surname><given-names>L</given-names></name><name><surname>Cannons</surname><given-names>JL</given-names></name><name><surname>Biancalana</surname><given-names>M</given-names></name><name><surname>Stoddard</surname><given-names>J</given-names></name><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Frucht</surname><given-names>DM</given-names></name><name><surname>Rao</surname><given-names>VK</given-names></name><name><surname>Atkinson</surname><given-names>TP</given-names></name><name><surname>Agharahimi</surname><given-names>A</given-names></name><name><surname>Hussey</surname><given-names>AA</given-names></name><name><surname>Folio</surname><given-names>LR</given-names></name><name><surname>Olivier</surname><given-names>KN</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Oliveira</surname><given-names>JB</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency</article-title><source>Nature Immunology</source><volume>15</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/ni.2771</pub-id><pub-id pub-id-type="pmid">24165795</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Hawse</surname><given-names>W</given-names></name><name><surname>Conter</surname><given-names>L</given-names></name><name><surname>Trivedi</surname><given-names>N</given-names></name><name><surname>Weisel</surname><given-names>F</given-names></name><name><surname>Wikenheiser</surname><given-names>D</given-names></name><name><surname>Cattley</surname><given-names>RT</given-names></name><name><surname>Shlomchik</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The AKT kinase signaling network is rewired by PTEN to control proximal BCR signaling in germinal center B cells</article-title><source>Nature Immunology</source><volume>20</volume><fpage>736</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0376-3</pub-id><pub-id pub-id-type="pmid">31011187</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzec</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kasprzycka</surname><given-names>M</given-names></name><name><surname>Witkiewicz</surname><given-names>A</given-names></name><name><surname>Raghunath</surname><given-names>PN</given-names></name><name><surname>El-Salem</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>E</given-names></name><name><surname>Odum</surname><given-names>N</given-names></name><name><surname>Wasik</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes</article-title><source>Blood</source><volume>111</volume><fpage>2181</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-06-095182</pub-id><pub-id pub-id-type="pmid">18025151</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>RD</given-names></name><name><surname>Welles</surname><given-names>HC</given-names></name><name><surname>Adams</surname><given-names>C</given-names></name><name><surname>Chakrabarti</surname><given-names>BK</given-names></name><name><surname>Gorman</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>R</given-names></name><name><surname>O’Dell</surname><given-names>S</given-names></name><name><surname>Lusvarghi</surname><given-names>S</given-names></name><name><surname>Bewley</surname><given-names>CA</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Sheng</surname><given-names>Z</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Wyatt</surname><given-names>R</given-names></name><name><surname>Kwong</surname><given-names>PD</given-names></name><name><surname>Mascola</surname><given-names>JR</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted isolation of antibodies directed against major sites of SIV Env vulnerability</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005537</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005537</pub-id><pub-id pub-id-type="pmid">27064278</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Igarashi</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Kano</surname><given-names>M</given-names></name><name><surname>Sugimoto</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Yuasa</surname><given-names>T</given-names></name><name><surname>Miyazawa</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Yasunami</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>O’Connor</surname><given-names>DH</given-names></name><name><surname>Watkins</surname><given-names>DI</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial</article-title><source>The Journal of Experimental Medicine</source><volume>199</volume><fpage>1709</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1084/jem.20040432</pub-id><pub-id pub-id-type="pmid">15210746</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattapallil</surname><given-names>JJ</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection</article-title><source>Nature</source><volume>434</volume><fpage>1093</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1038/nature03501</pub-id><pub-id pub-id-type="pmid">15793563</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Bohks</surname><given-names>SM</given-names></name><name><surname>KewalRamani</surname><given-names>VN</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Hope</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Recruitment of HIV and its receptors to dendritic cell-T cell junctions</article-title><source>Science</source><volume>300</volume><fpage>1295</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1126/science.1084238</pub-id><pub-id pub-id-type="pmid">12730499</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikell</surname><given-names>I</given-names></name><name><surname>Sather</surname><given-names>DN</given-names></name><name><surname>Kalams</surname><given-names>SA</given-names></name><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Alter</surname><given-names>G</given-names></name><name><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Characteristics of the earliest cross-neutralizing antibody response to HIV-1</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1001251</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1001251</pub-id><pub-id pub-id-type="pmid">21249232</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Malaspina</surname><given-names>A</given-names></name><name><surname>Ogwaro</surname><given-names>KM</given-names></name><name><surname>Donoghue</surname><given-names>ET</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><name><surname>Ehler</surname><given-names>LA</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Adelsberger</surname><given-names>J</given-names></name><name><surname>Lapointe</surname><given-names>R</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Baseler</surname><given-names>M</given-names></name><name><surname>Orenstein</surname><given-names>JM</given-names></name><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Mican</surname><given-names>JA</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals</article-title><source>PNAS</source><volume>98</volume><fpage>10362</fpage><lpage>10367</lpage><pub-id pub-id-type="doi">10.1073/pnas.181347898</pub-id><pub-id pub-id-type="pmid">11504927</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>MA</given-names></name><name><surname>Pedroza-Pacheco</surname><given-names>I</given-names></name><name><surname>Vandergrift</surname><given-names>NA</given-names></name><name><surname>Chui</surname><given-names>C</given-names></name><name><surname>Lloyd</surname><given-names>KE</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Soderberg</surname><given-names>KA</given-names></name><name><surname>Ogbe</surname><given-names>AT</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Verkoczy</surname><given-names>L</given-names></name><name><surname>Kelsoe</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Shea</surname><given-names>PR</given-names></name><name><surname>Connors</surname><given-names>M</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies</article-title><source>Science Immunology</source><volume>1</volume><elocation-id>aag0851</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aag0851</pub-id><pub-id pub-id-type="pmid">28783677</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Gray</surname><given-names>ES</given-names></name><name><surname>Wibmer</surname><given-names>CK</given-names></name><name><surname>Bhiman</surname><given-names>JN</given-names></name><name><surname>Nonyane</surname><given-names>M</given-names></name><name><surname>Sheward</surname><given-names>DJ</given-names></name><name><surname>Hermanus</surname><given-names>T</given-names></name><name><surname>Bajimaya</surname><given-names>S</given-names></name><name><surname>Tumba</surname><given-names>NL</given-names></name><name><surname>Abrahams</surname><given-names>M-R</given-names></name><name><surname>Lambson</surname><given-names>BE</given-names></name><name><surname>Ranchobe</surname><given-names>N</given-names></name><name><surname>Ping</surname><given-names>L</given-names></name><name><surname>Ngandu</surname><given-names>N</given-names></name><name><surname>Abdool Karim</surname><given-names>Q</given-names></name><name><surname>Abdool Karim</surname><given-names>SS</given-names></name><name><surname>Swanstrom</surname><given-names>RI</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Williamson</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape</article-title><source>Nature Medicine</source><volume>18</volume><fpage>1688</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1038/nm.2985</pub-id><pub-id pub-id-type="pmid">23086475</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moukambi</surname><given-names>F</given-names></name><name><surname>Rabezanahary</surname><given-names>H</given-names></name><name><surname>Rodrigues</surname><given-names>V</given-names></name><name><surname>Racine</surname><given-names>G</given-names></name><name><surname>Robitaille</surname><given-names>L</given-names></name><name><surname>Krust</surname><given-names>B</given-names></name><name><surname>Andreani</surname><given-names>G</given-names></name><name><surname>Soundaramourty</surname><given-names>C</given-names></name><name><surname>Silvestre</surname><given-names>R</given-names></name><name><surname>Laforge</surname><given-names>M</given-names></name><name><surname>Estaquier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Early loss of splenic Tfh cells in SIV-infected rhesus macaques</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1005287</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005287</pub-id><pub-id pub-id-type="pmid">26640894</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moukambi</surname><given-names>F</given-names></name><name><surname>Rabezanahary</surname><given-names>H</given-names></name><name><surname>Fortier</surname><given-names>Y</given-names></name><name><surname>Rodrigues</surname><given-names>V</given-names></name><name><surname>Clain</surname><given-names>J</given-names></name><name><surname>Benmadid-Laktout</surname><given-names>G</given-names></name><name><surname>Zghidi-Abouzid</surname><given-names>O</given-names></name><name><surname>Soundaramourty</surname><given-names>C</given-names></name><name><surname>Laforge</surname><given-names>M</given-names></name><name><surname>Estaquier</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mucosal T follicular helper cells in SIV-infected rhesus macaques: contributing role of IL-27</article-title><source>Mucosal Immunology</source><volume>12</volume><fpage>1038</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1038/s41385-019-0174-0</pub-id><pub-id pub-id-type="pmid">31114010</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakane</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e73453</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0073453</pub-id><pub-id pub-id-type="pmid">24039947</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yanagida</surname><given-names>R</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Akari</surname><given-names>H</given-names></name><name><surname>Yasutomi</surname><given-names>Y</given-names></name><name><surname>Miyazawa</surname><given-names>M</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Diversity of MHC class I genes in Burmese-origin rhesus macaques</article-title><source>Immunogenetics</source><volume>62</volume><fpage>601</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1007/s00251-010-0462-z</pub-id><pub-id pub-id-type="pmid">20640416</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neil</surname><given-names>SJD</given-names></name><name><surname>Zang</surname><given-names>T</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu</article-title><source>Nature</source><volume>451</volume><fpage>425</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature06553</pub-id><pub-id pub-id-type="pmid">18200009</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>CT</given-names></name><name><surname>Jaworski</surname><given-names>JP</given-names></name><name><surname>Jayaraman</surname><given-names>P</given-names></name><name><surname>Sutton</surname><given-names>WF</given-names></name><name><surname>Delio</surname><given-names>P</given-names></name><name><surname>Kuller</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Landucci</surname><given-names>G</given-names></name><name><surname>Richardson</surname><given-names>BA</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Forthal</surname><given-names>DN</given-names></name><name><surname>Haigwood</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques</article-title><source>Nature Medicine</source><volume>16</volume><fpage>1117</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1038/nm.2233</pub-id><pub-id pub-id-type="pmid">20890292</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Ramana</surname><given-names>CV</given-names></name><name><surname>Bayes</surname><given-names>J</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>33361</fpage><lpage>33368</lpage><pub-id pub-id-type="doi">10.1074/jbc.M105070200</pub-id><pub-id pub-id-type="pmid">11438544</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Gautam</surname><given-names>R</given-names></name><name><surname>Chun</surname><given-names>T-W</given-names></name><name><surname>Sadjadpour</surname><given-names>R</given-names></name><name><surname>Foulds</surname><given-names>KE</given-names></name><name><surname>Shingai</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>F</given-names></name><name><surname>Gazumyan</surname><given-names>A</given-names></name><name><surname>Golijanin</surname><given-names>J</given-names></name><name><surname>Donaldson</surname><given-names>M</given-names></name><name><surname>Donau</surname><given-names>OK</given-names></name><name><surname>Plishka</surname><given-names>RJ</given-names></name><name><surname>Buckler-White</surname><given-names>A</given-names></name><name><surname>Seaman</surname><given-names>MS</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Early antibody therapy can induce long-lasting immunity to SHIV</article-title><source>Nature</source><volume>543</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/nature21435</pub-id><pub-id pub-id-type="pmid">28289286</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Shiino</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Nakane</surname><given-names>T</given-names></name><name><surname>Iwamoto</surname><given-names>N</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Kawada</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Terahara</surname><given-names>K</given-names></name><name><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in burmese rhesus macaques</article-title><source>Journal of Virology</source><volume>86</volume><fpage>6481</fpage><lpage>6490</lpage><pub-id pub-id-type="doi">10.1128/JVI.07077-11</pub-id><pub-id pub-id-type="pmid">22491464</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>SL</given-names></name><name><surname>Hodgkin</surname><given-names>PD</given-names></name><name><surname>Tarlinton</surname><given-names>DM</given-names></name><name><surname>Corcoran</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The generation of antibody-secreting plasma cells</article-title><source>Nature Reviews. Immunology</source><volume>15</volume><fpage>160</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/nri3795</pub-id><pub-id pub-id-type="pmid">25698678</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omori</surname><given-names>SA</given-names></name><name><surname>Cato</surname><given-names>MH</given-names></name><name><surname>Anzelon-Mills</surname><given-names>A</given-names></name><name><surname>Puri</surname><given-names>KD</given-names></name><name><surname>Shapiro-Shelef</surname><given-names>M</given-names></name><name><surname>Calame</surname><given-names>K</given-names></name><name><surname>Rickert</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling</article-title><source>Immunity</source><volume>25</volume><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.015</pub-id><pub-id pub-id-type="pmid">17000121</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perfetto</surname><given-names>SP</given-names></name><name><surname>Chattopadhyay</surname><given-names>PK</given-names></name><name><surname>Lamoreaux</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>R</given-names></name><name><surname>Ambrozak</surname><given-names>D</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry</article-title><source>Journal of Immunological Methods</source><volume>313</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2006.04.007</pub-id><pub-id pub-id-type="pmid">16756987</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovas</surname><given-names>C</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Gerner</surname><given-names>MY</given-names></name><name><surname>Boswell</surname><given-names>KL</given-names></name><name><surname>Wloka</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>EC</given-names></name><name><surname>Ambrozak</surname><given-names>DR</given-names></name><name><surname>Sandler</surname><given-names>NG</given-names></name><name><surname>Timmer</surname><given-names>KJ</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Poholek</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>SS</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Alam</surname><given-names>SM</given-names></name><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><name><surname>Seder</surname><given-names>RA</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name><name><surname>Haddad</surname><given-names>EK</given-names></name><name><surname>Koup</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>CD4 T follicular helper cell dynamics during SIV infection</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>3281</fpage><lpage>3294</lpage><pub-id pub-id-type="doi">10.1172/JCI63039</pub-id><pub-id pub-id-type="pmid">22922258</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells</article-title><source>Nature Immunology</source><volume>7</volume><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/ni1302</pub-id><pub-id pub-id-type="pmid">16429138</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querec</surname><given-names>TD</given-names></name><name><surname>Akondy</surname><given-names>RS</given-names></name><name><surname>Lee</surname><given-names>EK</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Teuwen</surname><given-names>D</given-names></name><name><surname>Pirani</surname><given-names>A</given-names></name><name><surname>Gernert</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Marzolf</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Bennouna</surname><given-names>S</given-names></name><name><surname>Oluoch</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Vencio</surname><given-names>RZ</given-names></name><name><surname>Mulligan</surname><given-names>M</given-names></name><name><surname>Aderem</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans</article-title><source>Nature Immunology</source><volume>10</volume><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/ni.1688</pub-id><pub-id pub-id-type="pmid">19029902</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>Staron</surname><given-names>MM</given-names></name><name><surname>Shyer</surname><given-names>JA</given-names></name><name><surname>Ho</surname><given-names>P-C</given-names></name><name><surname>Marshall</surname><given-names>HD</given-names></name><name><surname>Gray</surname><given-names>SM</given-names></name><name><surname>Laidlaw</surname><given-names>BJ</given-names></name><name><surname>Araki</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name><name><surname>Kaech</surname><given-names>SM</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells</article-title><source>Immunity</source><volume>43</volume><fpage>690</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.017</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recher</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Hunziker</surname><given-names>L</given-names></name><name><surname>Freigang</surname><given-names>S</given-names></name><name><surname>Eschli</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Navarini</surname><given-names>A</given-names></name><name><surname>Senn</surname><given-names>BM</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Lötscher</surname><given-names>M</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name><name><surname>Zellweger</surname><given-names>R</given-names></name><name><surname>Hersberger</surname><given-names>M</given-names></name><name><surname>Theocharides</surname><given-names>A</given-names></name><name><surname>Hengartner</surname><given-names>H</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Deliberate removal of T cell help improves virus-neutralizing antibody production</article-title><source>Nature Immunology</source><volume>5</volume><fpage>934</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/ni1102</pub-id><pub-id pub-id-type="pmid">15300247</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recher</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Navarini</surname><given-names>A</given-names></name><name><surname>Hunziker</surname><given-names>L</given-names></name><name><surname>Lang</surname><given-names>PA</given-names></name><name><surname>Fink</surname><given-names>K</given-names></name><name><surname>Freigang</surname><given-names>S</given-names></name><name><surname>Georgiev</surname><given-names>P</given-names></name><name><surname>Hangartner</surname><given-names>L</given-names></name><name><surname>Zellweger</surname><given-names>R</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name><name><surname>Hegazy</surname><given-names>AN</given-names></name><name><surname>Eschli</surname><given-names>B</given-names></name><name><surname>Theocharides</surname><given-names>A</given-names></name><name><surname>Jeker</surname><given-names>LT</given-names></name><name><surname>Merkler</surname><given-names>D</given-names></name><name><surname>Odermatt</surname><given-names>B</given-names></name><name><surname>Hersberger</surname><given-names>M</given-names></name><name><surname>Hengartner</surname><given-names>H</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Extralymphatic virus sanctuaries as a consequence of potent T-cell activation</article-title><source>Nature Medicine</source><volume>13</volume><fpage>1316</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1038/nm1670</pub-id><pub-id pub-id-type="pmid">17982463</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuschl</surname><given-names>A-K</given-names></name><name><surname>Mesner</surname><given-names>D</given-names></name><name><surname>Shivkumar</surname><given-names>M</given-names></name><name><surname>Whelan</surname><given-names>MVX</given-names></name><name><surname>Pallett</surname><given-names>LJ</given-names></name><name><surname>Guerra-Assunção</surname><given-names>JA</given-names></name><name><surname>Madansein</surname><given-names>R</given-names></name><name><surname>Dullabh</surname><given-names>KJ</given-names></name><name><surname>Sigal</surname><given-names>A</given-names></name><name><surname>Thornhill</surname><given-names>JP</given-names></name><name><surname>Herrera</surname><given-names>C</given-names></name><name><surname>Fidler</surname><given-names>S</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name><name><surname>Maini</surname><given-names>MK</given-names></name><name><surname>Jolly</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells</article-title><source>Cell Reports</source><volume>39</volume><elocation-id>110650</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.110650</pub-id><pub-id pub-id-type="pmid">35417711</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickles</surname><given-names>RJ</given-names></name><name><surname>Botfield</surname><given-names>MC</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name><name><surname>Green</surname><given-names>OM</given-names></name><name><surname>Brugge</surname><given-names>JS</given-names></name><name><surname>Zoller</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Identification of Src, Fyn, Lyn, PI3K and Abl SH3 domain ligands using phage display libraries</article-title><source>The EMBO Journal</source><volume>13</volume><fpage>5598</fpage><lpage>5604</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1994.tb06897.x</pub-id><pub-id pub-id-type="pmid">7988556</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samer</surname><given-names>S</given-names></name><name><surname>Chowdhury</surname><given-names>A</given-names></name><name><surname>Wiche Salinas</surname><given-names>TR</given-names></name><name><surname>Estrada</surname><given-names>PMDR</given-names></name><name><surname>Reuter</surname><given-names>M</given-names></name><name><surname>Tharp</surname><given-names>G</given-names></name><name><surname>Bosinger</surname><given-names>S</given-names></name><name><surname>Cervasi</surname><given-names>B</given-names></name><name><surname>Auger</surname><given-names>J</given-names></name><name><surname>Gill</surname><given-names>K</given-names></name><name><surname>Ablanedo-Terrazas</surname><given-names>Y</given-names></name><name><surname>Reyes-Teran</surname><given-names>G</given-names></name><name><surname>Estes</surname><given-names>JD</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Paiardini</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Lymph-node-based CD3<sup>+</sup> CD20<sup>+</sup> cells emerge from membrane exchange between T follicular helper cells and B cells and increase their frequency following simian immunodeficiency virus infection</article-title><source>Journal of Virology</source><volume>97</volume><elocation-id>e0176022</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.01760-22</pub-id><pub-id pub-id-type="pmid">37223960</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sammicheli</surname><given-names>S</given-names></name><name><surname>Kuka</surname><given-names>M</given-names></name><name><surname>Di Lucia</surname><given-names>P</given-names></name><name><surname>de Oya</surname><given-names>NJ</given-names></name><name><surname>De Giovanni</surname><given-names>M</given-names></name><name><surname>Fioravanti</surname><given-names>J</given-names></name><name><surname>Cristofani</surname><given-names>C</given-names></name><name><surname>Maganuco</surname><given-names>CG</given-names></name><name><surname>Fallet</surname><given-names>B</given-names></name><name><surname>Ganzer</surname><given-names>L</given-names></name><name><surname>Sironi</surname><given-names>L</given-names></name><name><surname>Mainetti</surname><given-names>M</given-names></name><name><surname>Ostuni</surname><given-names>R</given-names></name><name><surname>Larimore</surname><given-names>K</given-names></name><name><surname>Greenberg</surname><given-names>PD</given-names></name><name><surname>de la Torre</surname><given-names>JC</given-names></name><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Iannacone</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammatory monocytes hinder antiviral B cell responses</article-title><source>Science Immunology</source><volume>1</volume><elocation-id>eaah6789</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aah6789</pub-id><pub-id pub-id-type="pmid">27868108</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>VT</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><name><surname>Franklin</surname><given-names>A</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Imami</surname><given-names>K</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Di Virgilio</surname><given-names>M</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PI3 kinase and FOXO1 transcription factor activity differentially control B cells in the germinal center light and dark zones</article-title><source>Immunity</source><volume>43</volume><fpage>1075</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.10.021</pub-id><pub-id pub-id-type="pmid">26620760</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarbassov</surname><given-names>DD</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</article-title><source>Science</source><volume>307</volume><fpage>1098</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1126/science.1106148</pub-id><pub-id pub-id-type="pmid">15718470</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>M</given-names></name><name><surname>Münch</surname><given-names>J</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><name><surname>Stahl-Hennig</surname><given-names>C</given-names></name><name><surname>Skowronski</surname><given-names>J</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Comprehensive analysis of nef functions selected in simian immunodeficiency virus-infected macaques</article-title><source>Journal of Virology</source><volume>78</volume><fpage>10588</fpage><lpage>10597</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.19.10588-10597.2004</pub-id><pub-id pub-id-type="pmid">15367626</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>M</given-names></name><name><surname>Münch</surname><given-names>J</given-names></name><name><surname>Kutsch</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Santiago</surname><given-names>ML</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F</given-names></name><name><surname>Müller-Trutwin</surname><given-names>MC</given-names></name><name><surname>Novembre</surname><given-names>FJ</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Courgnaud</surname><given-names>V</given-names></name><name><surname>Bailes</surname><given-names>E</given-names></name><name><surname>Roques</surname><given-names>P</given-names></name><name><surname>Sodora</surname><given-names>DL</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1</article-title><source>Cell</source><volume>125</volume><fpage>1055</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.04.033</pub-id><pub-id pub-id-type="pmid">16777597</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Berry</surname><given-names>J</given-names></name><name><surname>Dow</surname><given-names>C</given-names></name><name><surname>Bradley</surname><given-names>K</given-names></name><name><surname>Hoof</surname><given-names>I</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Hildebrand</surname><given-names>WH</given-names></name><name><surname>McMurtrey</surname><given-names>CP</given-names></name><name><surname>Wilson</surname><given-names>NA</given-names></name><name><surname>Watkins</surname><given-names>DI</given-names></name><name><surname>Mothé</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A shared MHC supertype motif emerges by convergent evolution in macaques and mice, but is totally absent in human MHC molecules</article-title><source>Immunogenetics</source><volume>64</volume><fpage>421</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s00251-011-0598-5</pub-id><pub-id pub-id-type="pmid">22322672</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehy</surname><given-names>AM</given-names></name><name><surname>Gaddis</surname><given-names>NC</given-names></name><name><surname>Choi</surname><given-names>JD</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein</article-title><source>Nature</source><volume>418</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nature00939</pub-id><pub-id pub-id-type="pmid">12167863</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Seki</surname><given-names>S</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IL-21-producer CD4+ T cell kinetics during primary simian immunodeficiency virus infection</article-title><source>Microbes and Infection</source><volume>15</volume><fpage>697</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2013.06.004</pub-id><pub-id pub-id-type="pmid">23791954</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>Z</given-names></name><name><surname>Gitlin</surname><given-names>AD</given-names></name><name><surname>Weinstein</surname><given-names>JS</given-names></name><name><surname>Lainez</surname><given-names>B</given-names></name><name><surname>Esplugues</surname><given-names>E</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Craft</surname><given-names>JE</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Dynamic signaling by T follicular helper cells during germinal center B cell selection</article-title><source>Science</source><volume>345</volume><fpage>1058</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1126/science.1257861</pub-id><pub-id pub-id-type="pmid">25170154</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silveira</surname><given-names>ELV</given-names></name><name><surname>Kasturi</surname><given-names>SP</given-names></name><name><surname>Kovalenkov</surname><given-names>Y</given-names></name><name><surname>Rasheed</surname><given-names>AU</given-names></name><name><surname>Yeiser</surname><given-names>P</given-names></name><name><surname>Jinnah</surname><given-names>ZS</given-names></name><name><surname>Legere</surname><given-names>TH</given-names></name><name><surname>Pulendran</surname><given-names>B</given-names></name><name><surname>Villinger</surname><given-names>F</given-names></name><name><surname>Wrammert</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies</article-title><source>Journal of Immunological Methods</source><volume>416</volume><fpage>69</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.11.003</pub-id><pub-id pub-id-type="pmid">25445326</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommerstein</surname><given-names>R</given-names></name><name><surname>Flatz</surname><given-names>L</given-names></name><name><surname>Remy</surname><given-names>MM</given-names></name><name><surname>Malinge</surname><given-names>P</given-names></name><name><surname>Magistrelli</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>N</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>Bergthaler</surname><given-names>A</given-names></name><name><surname>Igonet</surname><given-names>S</given-names></name><name><surname>Ter Meulen</surname><given-names>J</given-names></name><name><surname>Rigo</surname><given-names>D</given-names></name><name><surname>Meda</surname><given-names>P</given-names></name><name><surname>Rabah</surname><given-names>N</given-names></name><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Bowden</surname><given-names>TA</given-names></name><name><surname>Lambert</surname><given-names>PH</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Pinschewer</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection</article-title><source>PLOS Pathogens</source><volume>11</volume><elocation-id>e1005276</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005276</pub-id><pub-id pub-id-type="pmid">26587982</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>L</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Calado</surname><given-names>DP</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Paik</surname><given-names>JH</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Kearney</surname><given-names>JF</given-names></name><name><surname>Otipoby</surname><given-names>KL</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>PI3 kinase signals BCR-dependent mature B cell survival</article-title><source>Cell</source><volume>139</volume><fpage>573</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.08.041</pub-id><pub-id pub-id-type="pmid">19879843</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolp</surname><given-names>B</given-names></name><name><surname>Reichman-Fried</surname><given-names>M</given-names></name><name><surname>Abraham</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Giese</surname><given-names>SI</given-names></name><name><surname>Hannemann</surname><given-names>S</given-names></name><name><surname>Goulimari</surname><given-names>P</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name><name><surname>Grosse</surname><given-names>R</given-names></name><name><surname>Fackler</surname><given-names>OT</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HIV-1 Nef interferes with host cell motility by deregulation of Cofilin</article-title><source>Cell Host &amp; Microbe</source><volume>6</volume><fpage>174</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.06.004</pub-id><pub-id pub-id-type="pmid">19683683</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolp</surname><given-names>B</given-names></name><name><surname>Imle</surname><given-names>A</given-names></name><name><surname>Coelho</surname><given-names>FM</given-names></name><name><surname>Hons</surname><given-names>M</given-names></name><name><surname>Gorina</surname><given-names>R</given-names></name><name><surname>Lyck</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>JV</given-names></name><name><surname>Fackler</surname><given-names>OT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HIV-1 Nef interferes with T-lymphocyte circulation through confined environments in vivo</article-title><source>PNAS</source><volume>109</volume><fpage>18541</fpage><lpage>18546</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204322109</pub-id><pub-id pub-id-type="pmid">23093676</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swingler</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Swingler</surname><given-names>C</given-names></name><name><surname>Dauphin</surname><given-names>A</given-names></name><name><surname>Greenough</surname><given-names>T</given-names></name><name><surname>Jolicoeur</surname><given-names>P</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS</article-title><source>Cell Host &amp; Microbe</source><volume>4</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2008.05.015</pub-id><pub-id pub-id-type="pmid">18621011</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Takahara</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Shiino</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Iida</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Sakawaki</surname><given-names>H</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Igarashi</surname><given-names>T</given-names></name><name><surname>Koyanagi</surname><given-names>Y</given-names></name><name><surname>Naruse</surname><given-names>TK</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8+ T-cell responses in SIVmac239 infection of burmese rhesus macaques</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e54300</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054300</pub-id><pub-id pub-id-type="pmid">23342126</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terahara</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Shiino</surname><given-names>T</given-names></name><name><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection</article-title><source>Journal of Virology</source><volume>88</volume><fpage>14232</fpage><lpage>14240</lpage><pub-id pub-id-type="doi">10.1128/JVI.02032-14</pub-id><pub-id pub-id-type="pmid">25275131</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaras</surname><given-names>GD</given-names></name><name><surname>Yates</surname><given-names>NL</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Fouda</surname><given-names>GG</given-names></name><name><surname>Chavez</surname><given-names>LL</given-names></name><name><surname>Decamp</surname><given-names>AC</given-names></name><name><surname>Parks</surname><given-names>RJ</given-names></name><name><surname>Ashley</surname><given-names>VC</given-names></name><name><surname>Lucas</surname><given-names>JT</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Eron</surname><given-names>J</given-names></name><name><surname>Hicks</surname><given-names>CB</given-names></name><name><surname>Liao</surname><given-names>H-X</given-names></name><name><surname>Self</surname><given-names>SG</given-names></name><name><surname>Landucci</surname><given-names>G</given-names></name><name><surname>Forthal</surname><given-names>DN</given-names></name><name><surname>Weinhold</surname><given-names>KJ</given-names></name><name><surname>Keele</surname><given-names>BF</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Greenberg</surname><given-names>ML</given-names></name><name><surname>Morris</surname><given-names>L</given-names></name><name><surname>Karim</surname><given-names>SSA</given-names></name><name><surname>Blattner</surname><given-names>WA</given-names></name><name><surname>Montefiori</surname><given-names>DC</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name><name><surname>Haynes</surname><given-names>BF</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia</article-title><source>Journal of Virology</source><volume>82</volume><fpage>12449</fpage><lpage>12463</lpage><pub-id pub-id-type="doi">10.1128/JVI.01708-08</pub-id><pub-id pub-id-type="pmid">18842730</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volcic</surname><given-names>M</given-names></name><name><surname>Sparrer</surname><given-names>KMJ</given-names></name><name><surname>Koepke</surname><given-names>L</given-names></name><name><surname>Hotter</surname><given-names>D</given-names></name><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Stürzel</surname><given-names>CM</given-names></name><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Stamminger</surname><given-names>T</given-names></name><name><surname>Hofmann</surname><given-names>TG</given-names></name><name><surname>Arhel</surname><given-names>NJ</given-names></name><name><surname>Wiesmüller</surname><given-names>L</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Vpu modulates DNA repair to suppress innate sensing and hyper-integration of HIV-1</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1247</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0753-6</pub-id><pub-id pub-id-type="pmid">32690953</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sohn</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>G</given-names></name><name><surname>Milner</surname><given-names>JD</given-names></name><name><surname>Pierce</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The autoinhibitory C-terminal SH2 domain of phospholipase C-γ2 stabilizes B cell receptor signalosome assembly</article-title><source>Science Signaling</source><volume>7</volume><elocation-id>ra89</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005392</pub-id><pub-id pub-id-type="pmid">25227611</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>JB</given-names></name><name><surname>Hill</surname><given-names>AL</given-names></name><name><surname>Sanisetty</surname><given-names>S</given-names></name><name><surname>Penaloza-MacMaster</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Shetty</surname><given-names>M</given-names></name><name><surname>Parenteau</surname><given-names>L</given-names></name><name><surname>Cabral</surname><given-names>C</given-names></name><name><surname>Shields</surname><given-names>J</given-names></name><name><surname>Blackmore</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JY</given-names></name><name><surname>Brinkman</surname><given-names>AL</given-names></name><name><surname>Peter</surname><given-names>LE</given-names></name><name><surname>Mathew</surname><given-names>SI</given-names></name><name><surname>Smith</surname><given-names>KM</given-names></name><name><surname>Borducchi</surname><given-names>EN</given-names></name><name><surname>Rosenbloom</surname><given-names>DIS</given-names></name><name><surname>Lewis</surname><given-names>MG</given-names></name><name><surname>Hattersley</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Hesselgesser</surname><given-names>J</given-names></name><name><surname>Geleziunas</surname><given-names>R</given-names></name><name><surname>Robb</surname><given-names>ML</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Michael</surname><given-names>NL</given-names></name><name><surname>Barouch</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys</article-title><source>Nature</source><volume>512</volume><fpage>74</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/nature13594</pub-id><pub-id pub-id-type="pmid">25042999</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wülfing</surname><given-names>C</given-names></name><name><surname>Sjaastad</surname><given-names>MD</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Visualizing the dynamics of T cell activation: intracellular adhesion molecule 1 migrates rapidly to the T cell/B cell interface and acts to sustain calcium levels</article-title><source>PNAS</source><volume>95</volume><fpage>6302</fpage><lpage>6307</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6302</pub-id><pub-id pub-id-type="pmid">9600960</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Santini</surname><given-names>PA</given-names></name><name><surname>Sullivan</surname><given-names>JS</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>SC</given-names></name><name><surname>Dyer</surname><given-names>WB</given-names></name><name><surname>Ketas</surname><given-names>TJ</given-names></name><name><surname>Chadburn</surname><given-names>A</given-names></name><name><surname>Cohen-Gould</surname><given-names>L</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Sanders</surname><given-names>RW</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Cerutti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits</article-title><source>Nature Immunology</source><volume>10</volume><fpage>1008</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1038/ni.1753</pub-id><pub-id pub-id-type="pmid">19648924</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Malam</surname><given-names>N</given-names></name><name><surname>Aye</surname><given-names>PP</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Lackner</surname><given-names>AA</given-names></name><name><surname>Veazey</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Persistent simian immunodeficiency virus infection drives differentiation, aberrant accumulation, and latent infection of germinal center follicular T helper cells</article-title><source>Journal of Virology</source><volume>90</volume><fpage>1578</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1128/JVI.02471-15</pub-id><pub-id pub-id-type="pmid">26608323</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>E</given-names></name><name><surname>Nakaoka</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>L</given-names></name><name><surname>Reith</surname><given-names>E</given-names></name><name><surname>Langer</surname><given-names>S</given-names></name><name><surname>Hopfensperger</surname><given-names>K</given-names></name><name><surname>Iwami</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>G</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Koyanagi</surname><given-names>Y</given-names></name><name><surname>Sauter</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Human-specific adaptations in Vpu conferring anti-tetherin activity are critical for efficient early HIV-1 replication in vivo</article-title><source>Cell Host &amp; Microbe</source><volume>23</volume><fpage>110</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.12.009</pub-id><pub-id pub-id-type="pmid">29324226</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Kawada</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Igarashi</surname><given-names>H</given-names></name><name><surname>Matano</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Post-infection immunodeficiency virus control by neutralizing antibodies</article-title><source>PLOS ONE</source><volume>2</volume><elocation-id>e540</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000540</pub-id><pub-id pub-id-type="pmid">17579714</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Shun</surname><given-names>MC</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>C</given-names></name><name><surname>Skowronski</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells</article-title><source>PNAS</source><volume>116</volume><fpage>9568</fpage><lpage>9577</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818401116</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Landford</surname><given-names>WC</given-names></name><name><surname>Virgen</surname><given-names>B</given-names></name><name><surname>Gregory</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>MC</given-names></name><name><surname>Munch</surname><given-names>J</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Bieniasz</surname><given-names>PD</given-names></name><name><surname>Hatziioannou</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nef proteins from simian immunodeficiency viruses are tetherin antagonists</article-title><source>Cell Host &amp; Microbe</source><volume>6</volume><fpage>54</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.05.008</pub-id><pub-id pub-id-type="pmid">19501037</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zotos</surname><given-names>D</given-names></name><name><surname>Coquet</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Light</surname><given-names>A</given-names></name><name><surname>D’Costa</surname><given-names>K</given-names></name><name><surname>Kallies</surname><given-names>A</given-names></name><name><surname>Corcoran</surname><given-names>LM</given-names></name><name><surname>Godfrey</surname><given-names>DI</given-names></name><name><surname>Toellner</surname><given-names>K-M</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name><name><surname>Tarlinton</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism</article-title><source>The Journal of Experimental Medicine</source><volume>207</volume><fpage>365</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1084/jem.20091777</pub-id><pub-id pub-id-type="pmid">20142430</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88849.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kirchhoff</surname><given-names>Frank</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Ulm University Medical Center</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>Yamamoto and Matano provide <bold>convincing</bold> evidence that a G63E/R CD8+ T-cell escape mutation in the accessory viral protein Nef promote the induction of neutralizing antibody (nAb) responses in rhesus macaques infected with SIVmac239, which is usually largely resistant to neutralization. Functional analyses support that this mutation specifically impairs Nef’s ability to stimulate PI3K/Akt/mTORC2 signaling. This <bold>important</bold> study suggests that the accessory viral protein Nef impairs B cell function and effective humoral immune responses and is of interest for researchers and physicians interested in HIV/AIDS and vaccine development.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88849.4.sa1</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Human and simian immunodeficiency viruses (HIV and SIV, respectively) evolved numerous mechanisms to compromise effective immune responses but the underlying mechanisms remain incompletely understood. Here, Yamamoto and Matano examined the humoral immune response in a large number of rhesus macaques infected with the difficult-to-neutralize SIVmac239 strain and identified a subgroup of animals showing significant neutralizing Ab responses. Sequence analyses revealed that in most of these animals (7/9) but only a minority in the control group (2/19) SIVmac variants containing a CD8+ T-cell escape mutation of G63E/R in the viral Nef gene emerged. Functional analyses revealed that this change attenuates the ability of Nef to stimulate PI3K/Akt/mTORC2 signalling. The authors propose that this improved induction of SIVmac239 nAb is reciprocal to antibody dysregulation caused by a previously identified human PI3K gain-of-function mutation associated with impaired anti-viral B-cell responses. Altogether, the results suggest that PI3K signalling plays a role in B-cell maturation and generation of effective nAb responses. Preliminary data indicate that Nef might be transferred from infected T cells to B cells by direct contact. However, the exact mechanism and the relevance for vaccine development requires further studies</p><p>The strengths of the study are that the authors analyzed a large number of SIVmac-infected macaques to unravel the biological significance of the known effect of the interaction of Nef with PI3K/Akt/mTORC2 signaling. This is interesting and may provide a novel means to improve humoral immune responses to HIV. In the revised version the authors made an effort to address previous concerns. Especially, they provide data supporting that Nef might be transferred to B cells by direct cell-cell contact. In addition, they provide some evidence that G63R that also emerged in most animals does not share the disruptive effect of G63G although experimental examination and discussion why G63R might emerge remains poor. A weakness that remains is that some effects of the G63E mutation are modest and effects were not compared to SIVmac constructs lacking Nef entirely. The evidence for a role of Nef G63E mutation on PI3K and the association with improved nAb responses is convincing and it is appreciated that the authors provide additional evidence for a potential impact of &quot;soluble&quot; Nef on neighboring B cells. The presentation of the experimental set-up and the results has been improved but is in part still challenging to comprehend. It seems that direct cell-cell contact is required and membranes are exchanged. Since Nef is associated with cellular membranes this might lead to some transfer of Nef to B cells. However, the immunological and functional consequences of this largely remain to be determined. Alternatively, Nef-mediated manipulation of helper CD4 T cells might also impact B cell function and effective humoral immune responses. Additional editing of the manuscript has been performed to make the results accessible to a broad readership.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88849.4.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Hiroyuki</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Infectious Diseases</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Matano</surname><given-names>Tetsuro</given-names></name><role specific-use="author">Author</role><aff><institution>National Institute of Infectious Diseases</institution><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>Human and simian immunodeficiency viruses (HIV and SIV, respectively) evolved numerous mechanisms to compromise effective immune responses but the underlying mechanisms remain incompletely understood. Here, Yamamoto and Matano examined the humoral immune response in a large number of rhesus macaques infected with the difficult-to-neutralize SIVmac239 strain and identified a subgroup of animals showing significant neutralizing Ab responses. Sequence analyses revealed that in most of these animals (7/9) but only a minority in the control group (2/19) SIVmac variants containing a CD8+ T-cell escape mutation of G63E/R in the viral Nef gene emerged. Functional analyses revealed that this change attenuates the ability of Nef to stimulate PI3K/Akt/mTORC2 signalling. The authors propose that this improved induction of SIVmac239 nAb is reciprocal to antibody dysregulation caused by a previously identified human PI3K gain-of-function mutation associated with impaired anti-viral B-cell responses. Altogether, the results suggest that PI3K signalling plays a role in B-cell maturation and generation of effective nAb responses. Preliminary data indicate that Nef might be transferred from infected T cells to B cells by direct contact. However, the exact mechanism and the relevance for vaccine development requires further studies</p><p>Strengths of the study are that the authors analyzed a large number of SIVmac-infected macaques to unravel the biological significance of the known effect of the interaction of Nef with PI3K/Akt/mTORC2 signaling. This is interesting and may provide a novel means to improve humoral immune responses to HIV. In the revised version the authors made an effort to address previous concerns. Especially, they provide data supporting that Nef might be transferred to B cells by direct cell-cell contact. In addition, the provide some evidence that G63R that also emerged in most animals does not share the disruptive effect of G63G although experimental examination and discussion why G63R might emerge remains poor. Another weakness that remains is that some effects of the G63E mutation are modest and effects were not compared to SIVmac constructs lacking Nef entirely. The evidence for a role of Nef G63E mutation on PI3K and the association with improved nAb responses was largely convincing and it is appreciated that the authors provide additional evidence for a potential impact of &quot;soluble&quot; Nef on neighboring B cells. However, the experimental set-up and the results are difficult to comprehend. It seems that direct cell-cell contact is required and membranes are exchanged. Since Nef is associated with cellular membranes this might lead to some transfer of Nef to B cells. However, the immunological and functional consequences of this remain largely elusive. Alternatively, Nef-mediated manipulation of helper CD4 T cells might also impact B cell function and effective humoral immune responses. As previously noted, the presentation of the results and conclusions was in part very convoluted and difficult to comprehend. While the authors made attempts to improve the writing parts of the manuscript are still challenging to follow. This applies even more to the rebuttal (complex words combined with poor grammar), which made it difficult to assess which concerns have been satisfactory addressed.</p></disp-quote><p>We are grateful for the visionary comments. Based on suggestion, we have edited the writing throughout and appended remarks on certain points raised in the Discussion section. For points that need experimentation, we would like to address them in a follow-up study now under preparation.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Additional editing of the manuscript is highly recommended to make the results accessible for a broad readership.</p></disp-quote><p>We are grateful for the important suggestion. Accordingly, we have made editing of the manuscript aimed for a broad readership.</p></body></sub-article></article>